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SUMMARY 
 
Background. Age-related macular degeneration (AMD) is a multifactorial retinal 
neurodegenerative disorder and the leading cause of blindness among the elderly 
worldwide. Genetics is one of several factors which play role in the pathogenesis. An 
AMD-risk locus on chromosome 10q26 spans two genes namely age-related 
maculopathy susceptibility 2 (ARMS2) and high temperature requirement factor A1 
(HTRA1). Controversy exists as to which of the two genes are responsible for 
increased risk of the disease. HTRA1 is a secreted serine protease reported to play a 
crucial role in the development of several cancers and neurodegenerative diseases. 
ARMS2 is a primate-specific gene and, so far, biological properties attributed to the 
putative protein remain elusive. Two synonymous single nucleotide polymorphisms 
(SNPs) in exon 1 of HTRA1 are in complete linkage disequilibrium with several 
polymorphisms within 10q26 locus which are strongly associated with AMD. 
 
Aim. The aim of the study was to assess an effect of AMD-associated synonymous 
SNPs on the structure and function of HTRA1. In addition, a putative role of HTRA1 
on activation of microglia was investigated. 
 
Methods. Differences in the structures of recombinant non-risk- and risk-associated 
HTRA1 isoforms were analyzed by MicroScale Thermophoresis (MST) and limited 
partial proteolysis. The secretion of the different HTRA1 isoforms was analyzed after 
heterologous expression in Hek293-Ebna cells. By employing MST and in vitro 
digestion assays, the interaction of HTRA1 isoforms with reported interaction 
partners, transforming growth factor-β1 (TGF-β1) and β-casein, was compared. 
Luciferase assays were applied to compare the regulation of TGF-β1 signaling by 
different HTRA1 isoforms in MLEC-PAI/Luc cells (Mink lung epithelial cells stably 
transfected with an expression construct containing a truncated PAI-1 promoter fused 
to the firefly luciferase reporter gene). The influence of HTRA1 non-risk- and risk-
associated isoforms was also analyzed on autocrine TGF-β signaling in BV-2 
microglial cells addressing protein and transcript levels. Finally, an effect of HTRA1 
on classical (M1) and alternative (M2) activation of microglia was assessed by 
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treating BV-2 cells with known stimulators for both pathways in presence of purified 
recombinant HTRA1. The gene expression of markers of M1 and M2 activation as 
well as nitrite production by M1 microglial cells were investigated. 
 
Results. MST and limited partial proteolysis showed that the conformation of the 
AMD risk-associated HTRA1 protein is different from that of the non-risk-associated 
HTRA1 isoforms. The risk-associated isoform was also found to have decreased 
secretion. While there was no difference of the HTRA1 isoforms in casein binding 
and digestion, the risk-associated isoform exhibited no binding and decreased 
digestion of TGF-β1. This eventually affected the regulation of TGF-β signaling in 
MLEC-PAI/Luc cells and microglial cells. In addition, preliminary data indicate that 
HTRA1 might be a regulator of M2 microglial activation induced by IL4 and TGF-β1. 
Nevertheless, more experiments are required to support the role of HTRA1 on 
microglial activation. 
 
Conclusion. Our data show an effect of AMD-associated synonymous polymorph-
isms on HTRA1 secretion and protein structure, thereby affecting the capacity of 
HTRA1 to regulate TGF-β signaling. Whether this plays a role in pathogenesis of 
AMD still remains to be clarified. 
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1. INTRODUCTION 
1.1. Age-related Macular Degeneration (AMD) 
Age-related macular degeneration (AMD) is one of the leading causes of irreversible 
blindness of elderly population worldwide (Resnikoff et al., 2004). First, the condition 
was described in medical literature as “symmetrical central choroido-retinal disease 
occurring in senile persons” in 1874 (Hutchinson et al., 1874). AMD is a multifactorial 
neurodegenerative disease characterized by progressive degeneration of 
photoreceptors/retinal pigment epithelial (RPE) complex primarily in macular region 
of the retina, which has the highest concentration of cone photoreceptors and is 
responsible for visual acuity (Curcio et al., 1990; Smith et al., 2001; Klein et al., 
2010). It is a complex disease owing to multiple risk factors such as age, diet, 
smoking, oxidative stress and genetics (Klein et al., 2010). The disease is associated 
not only with visual impairment but also with high rates of depression, anxiety and 
emotional distress (Berman and Brodaty, 2006). A recent meta-analysis has shown 
that 8.7% of the worldwide population has AMD, and the projected number of people 
with the disease is around 196 million in 2020, increasing to 288 million in 2040 
(Wong et al., 2014). 
 
1.1.1. Anatomy of healthy human retina 
The human retina is a light-sensitive layer lining the inside of the posterior segment 
of the eye (Yanoff et al., 2009). It consists of two distinct layers: 1) the neuroretina 
consisting of photoreceptor cells, neuronal cells and glial cells; and 2) the RPE 
separated from the neuroretina by a virtual subretinal space. When light entering the 
eye is focused on the retina, the neuroretina serves to convert light into neural 
signals. A complex neural circuitry within the retina relays these signals to visual 
centres in the brain (Luo et al., 2008). Retinal photoreceptors are metabolically 
active neurons with oxygen requirements that are among the highest in the human 
body (Wong-Riley, 2010). The outer segments of photoreceptors comprise stacks of 
flattened membranous discs containing light-sensitive photopigments (rhodopsin in 
rods and spectrally tuned red-, green- or blue-sensitive opsins in cones). The macula 
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(Latin for “spot”) is a distinct feature of human and most non-human primate retina 
and lies in the central visual axis. The human macula (about 6 mm in diameter) 
contains a cone-dominated fovea (0.8 mm in diameter) that is associated with high-
acuity vision (Curcio et al., 1990) (Figure 1A and B). 
 
 
Figure 1: Anatomy of retina. (A) Anatomical depiction of the human eye viewed in 
sagittal section; (B) Fundus photograph of the retina of a healthy individual, using an 
ophthalmoscope; (C) Confocal microscopy image of a human retina labeled with 
fluorescent probes. Cell nuclei in the outer nuclear layer of photoreceptors are 
indicated by red, photoreceptor outer segments are green and structures containing 
high concentrations of filamentous actin (cell–cell junctions and vessel walls) are 
blue. Adapted and modified from Fritsche et al. (2014). 
 
The RPE, which constitutes the outer blood-retinal barrier (BRB) (Bernstein and 
Hollenberg, 1965), facilitates photoreceptor turnover by phagocytosis and lysosomal 
degradation of outer segments following shedding (Young, 1969; LaVail, 1983). 
Moreover, the RPE serves as an excellent support system to the neuroretina, by 
delivery of oxygen and metabolites to the photoreceptors, preventing extracellular 
fluid leaking into the subretinal space from the underlying choriocapillaris (a 
continuous layer of fenestrated capillaries), actively pumping fluid out of the 
subretinal space and regulating trafficking of immune cells across the BRB (Forrester 
and Xu, 2012). The inner aspect of the choroid, next to the RPE, is Bruch’s 
Membrane (BrM), a laminar extracellular matrix (ECM) of collagen and elastin 
(Curcio et al., 2013). BrM works as a supply chain by transporting oxygen, glucose 
and other metabolites to RPE and photoreceptors, and returns metabolic wastes to 
systemic circulation (Booij et al., 2010). Integrity of the BrM appears to be important 
in suppressing invasion of vessels from the choroidal circulation into the retina 
(Chong et al., 2005). The choriocapillaris arises from the branches of posterior ciliary 
arteries and supplies the photoreceptor-RPE complex and outer neuroretina, while 
the inner parts of the neuroretina are supplied by the central retinal artery (Bernstein 
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and Hollenberg, 1965). Figure 1C shows the order of photoreceptors, RPE, Bruch’s 
membrane and choroidal blood vessels in a confocal microscopy image of a human 
retinal section. 
 
1.1.2. Pathology and pathogenesis of AMD 
A general hallmark of aging retina is the accumulation of lipofuscin in the lysosomal 
compartments and the cytoplasm of RPE cells. Lipofuscin are autofluorescent 
granules that are remnants of retinoid metabolites from shed photoreceptor outer-
segment membranes. A2E, an abundant component of lipofuscin (Delori et al., 2001; 
Strauss, 2005) is hypothesized to exacerbate AMD through photo-oxidation and 
phototoxicity in RPE cells (Sparrow and Boulton, 2005). The photo-oxidation could 
serve as a trigger for activation of the complement system, a trigger that would 
thereby predispose the macula to disease and contribute to the chronic inflammatory 
processes observed in AMD pathogenesis. Furthermore, the excessive accumulation 
of lipofuscin and the consequent activation of the complement cascade might, over 
time, also contribute to the formation of drusen (Zhou et al., 2006; Zhou et al., 2009). 
Drusen are cellular debris at the interface between RPE and BrM (or between RPE 
and neuroretina). Drusen are classified as small (<63 μm in diameter with discrete 
margins), medium (63–124 μm) or large (>125 μm with indistinct edges) (Ferris et 
al., 2005). In a recent study, using a combination of high-resolution analytical 
techniques, tiny hydroxyapatite (bone mineral) spherules with cholesterol-containing 
cores are found in all examined drusen, which may be responsible for initiation of 
drusen formation (Thompson et al., 2015). Drusen components include lipids and an 
array of proteins, including those involved in complement regulation, Tissue Inhibitor 
of Matrixmetalloproteases-3 (TIMP3), vitronectin, β-amyloid and apolipoproteins (E, 
B, A-I, C-I and C-II), plus zinc and iron ions (Arnhold et al., 1998; Mullins et al., 2000; 
Crabb et al., 2002). AMD patients display a broad spectrum of clinical characteristics 
based upon drusen size and AMD pigmentary abnormalities, both hypopigmentation 
and hyperpigmentation. Clinical examination of human retinas can reveal distinct 
hallmarks of AMD that can be broadly divided into early/intermediate and late 
(advanced) stages. Age-Related Eye Disease Study (AREDS) has developed a five-
step severity scale to define risk categories for development of advanced AMD. Early 
or intermediate AMD (AREDS grades 2 and 3) is the most common and least severe 
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form. Late AMD (AREDS grades 4 and 5) is usually subdivided into dry [geographic 
atrophy (GA)] and wet [choroidal neovascularization (CNV)] (Ferris et al., 2005). 
These pathological hallmarks of early AMD and late AMD (GA and CNV) are shown 
in Figure 2. The AREDS grades and their characteristics are listed in Table 1. 
 
 
 
Figure 2: Pathological hallmarks of early AMD and late AMD revealed by 
fundus photography. (A) Eye with drusen: visible as small yellow spots; (B) wet 
AMD: eye with choroidal neovascularization and exudation; (C) dry AMD: eye with 
advanced geographic atrophy. Adapted from Ratnapriya and Chew (2013).  
 
Table 1: Stages of AMD divided into AREDS categories according to 
characteristics  
AREDS 
Category 
Stages of AMD Characteristics 
Category 1  No AMD A few small or no drusen 
Category 2 Early Stage 
AMD 
Several small drusen or a few medium-sized 
drusen in one or both eyes 
Category 3 Intermediate 
AMD 
Many medium-sized drusen or one or more 
large drusen in one or both eyes 
Category 4 and 
5 
Advanced AMD In one eye only, either a break-down of light-
sensitive cells and supporting tissue in the 
central retinal area (advanced dry form), or 
abnormal and fragile blood vessels under the 
retina (wet form) 
 
To date, although no cure of dry AMD is available, the only available therapy for 
management of dry AMD is daily intake of antioxidant formulation (Age-Related Eye 
Disease Study Research, 2001; Age-Related Eye Disease Study 2 Research, 2013). 
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According to the first AREDS, combination of the following different antioxidants was 
administered: vitamin C (500 mg), vitamin E (400 international units [IU]), beta-
carotene (15 mg), zinc (80 mg) and copper (2 mg). AREDS2 study suggested that 
lutein/zeaxanthin could be more appropriate than beta carotene in the AREDS-type 
supplements. Other promising antioxidants for dry AMD therapy include crocetin 
(Maccarone et al., 2008), curcumin (Mandal et al., 2009; Chang et al., 2014), 
Resveratrol (King et al., 2005; Nagineni et al., 2014), and vitamins B9, B12 and B6 
(Christen et al., 2009). Besides antioxidants, new findings about pathogenesis of 
AMD have led to several potential therapeutic strategies (Buschini et al., 2015). Both 
AMD drusen and Alzheimer’s disease plaques contain amyloid beta (Aβ) plaques, 
which are in strong association with activated complement components (Johnson et 
al., 2002; Ohno-Matsui, 2011). Humanized monoclonal antibodies: RN6G (Pfizer, 
New York, NY, USA) and GSK933776 (GlaxoSmithKline, Verona, Italy) (Ding et al., 
2008; Ding et al., 2011) and a drug named glatiramer acetate (Butovsky et al., 
2006a; Landa et al., 2008), directed against Aβ plaques, have been demonstrated to 
reduce drusen in AMD mice model and are undergoing clinical trials. Another group 
of drugs (fenretinide, ACU-4429 ALK-001) which showed reduction in accumulation 
of A2E and lipofuscin also presents an exciting possibility for treating AMD (Mata et 
al., 2013; Holz et al., 2014). Development of stem cell therapy for treatment of dry 
AMD is another promising strategy (Brandl et al., 2015). Development of surgical 
procedures to transplant human embryonic stem cells, which are able to differentiate 
into RPE cells, is currently under clinical trials (Carr et al., 2013). 
The wet form, also known as neovascular or exudative AMD, constitutes only 10–
15% of all AMD cases, but accounts for at least 80% of AMD-related blindness 
(Scholl et al., 2009). In this case, accelerated and profound visual loss typically 
occurs as a result of CNV, where new vessels grow and invade the retina resulting in 
sub-RPE or subretinal haemorrhages, or fluid accumulation in or below the layers of 
the retina (Ferris et al., 1984). In contrast to the typical slow progression of GA, CNV 
can decrease vision acutely through the abrupt onset of edema and bleeding from 
new capillaries invading the RPE and neural retina. Vascular endothelial growth 
factor (VEGF) has been implicated as a key mediator in the pathogenesis of CNV 
(Kvanta et al., 1996; Barouch and Miller, 2004; Adamis and Shima, 2005). CNV can 
be treated but not be cured with intraocular anti-VEGF antibodies (Ferris, 2004; 
INTRODUCTION 
 
8 | P a g e   
Gragoudas et al., 2004; Rosenfeld et al., 2011). Two most widely used monoclonal 
antibodies against VEGF are bevacizumab (Avastin™; Genentech, South San 
Francisco, CA, USA), a full-length, humanized monoclonal antibody against VEGF; 
and ranibizumab (Lucentis™; Genentech, South San Francisco, CA, USA), a 
recombinant, humanized, monoclonal antibody fragment directed toward all isoforms 
of VEGF-A (Presta et al., 1997; Chen et al., 1999; Ferrara et al., 2004). These 
antibodies bind and neutralize all the biologically active forms of VEGF and thereby 
inhibit angiogenesis. Aflibercept (VEGF trap-eye), a fusion protein consisting of key 
domains of the human VEGF1 and VEGF2 receptors coupled to the Fc part of a 
human IgG molecule, has been approved recently for neovascular AMD (Grisanti et. 
al, 2013). It is suggested by a theoretical model that Aflibercept may have a longer 
duration of action compared with other treatments (Ohr and Kaiser, 2012).  
 
1.1.2.1. Role of microglia in AMD pathogenesis 
Microglial cells are specialized immune cells that reside in the brain and retina, and 
are responsible for the initial detection of noxious stimuli arising in the local micro-
environment (Kettenmann et al., 2011). Microglia are functionally different from 
blood-derived macrophages, which originate from bone marrow-derived monocytes 
and enter the CNS and retina during pathological conditions. Microglia are believed 
to originate from macrophages produced by primitive haematopoiesis in the yolk sac 
(Alliot et al., 1999). Morphologically, microglia are very adaptable, changing their 
phenotype depending on location and role (Gehrmann et al., 1995).  
In the healthy retina, microglia are distributed throughout the inner and outer 
plexiform layers, where they carry out constant and dynamic surveillance of the 
extracellular microenvironment (Lee et al., 2008). In the resting state, they 
continuously scan the local environment and phagocytose cell debris (Figure 3A). 
Any detection of signs for challenges in the retina, leading to dysfunctions or 
degenerations in the RPE, photoreceptor layer and the ganglion cell, rapidly alert the 
microglia (Figure 3B). In the effector phase, microglia migrate to the lesion sites, 
accumulate in the nuclear layers and the subretinal space and subsequently turn into 
amoeboid phagocytes (Figure 3C). 
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This complex, multistage activation process converts the “resting microglial cells” 
into the “activated microglial cell” (Kettenmann et al., 2011). Microglia exhibit 
different states of activation, termed as proinflammatory M1 activation which includes 
“classical activation”, and anti-inflammatory M2 activation which includes “alternative 
activation” and “acquired deactivation”, depending on the milieu in which they 
become activated and the factors they are stimulated by (Le et al., 2001; Li et al., 
2004; Block et al., 2007).  
 
Figure 3: Schematic representation of three common phases of microglial 
activity in the retina. (A) Resting phase (B) Activation phase (C) Effector phase. 
Pink cell bodies indicate microglia; yellow stars: insults or injury; RPE: retinal 
pigment epithelium; ONL: outer nuclear layer; OPL: outer plexiform layer; INL: inner 
nuclear layer; IPL: inner plexiform layer; GCL: ganglion cell layer. Adapted and 
modified from Karlstetter et al. (2010). 
 
Microglial cell bodies, typically situated in the inner retina in the normal human eye 
(Combadiere et al., 2007) can migrate to the subretinal space (the potential space 
between the photoreceptor outer segments and the apical surface of the RPE cells) 
in response to inflammatory stimuli (Gupta et al., 2003; Xu et al., 2009). Activated 
microglia have been found in the outer retina and subretinal space in eyes with AMD 
(Gupta et al., 2003; Combadiere et al., 2007). Retinal microglia express the 
chemokine receptor CX3CR1. Genetic polymorphisms in the CX3CR1 gene have 
been associated with AMD and reduce the chemotactic ability of monocytes 
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(Combadiere et al., 2007). In CX3CR1-deficient mice, accumulation of microglia and 
macrophages in the subretinal space has been observed, contributing to drusen 
formation and photoreceptors degeneration (Combadiere et al., 2007; Sennlaub et 
al., 2013). 
 
1.1.3. Etiology of AMD 
Based on epidemiology and pathobiology, prevalence of AMD phenotypes depends 
on several risk factors: aging, environmental factors, demographic factors and 
genetic factors (Leveziel et al., 2011; Ratnapriya and Chew, 2013; Fritsche et al., 
2014). 
 
1.1.3.1. Aging 
As numerous population-based studies indicate, AMD is particularly prevalent in 
people who are 60 years and older (Mitchell et al., 1995; Klein et al., 1999a; Klaver 
et al., 2001; Wong et al., 2008; Wong et al., 2014). Though aging might not be 
enough to trigger AMD single-handedly, along with genetic and environmental risk 
factors the pathological changes of AMD become more likely. Aging-associated 
expression changes in genes associated with mitochondrial function, protein 
metabolism and immune response have been identified in several tissues (Zahn et 
al., 2007) and are consistent with some proposed mechanisms for late-onset 
neurodegenerative diseases (Wright et al., 2004; Lin and Beal, 2006; Rubinsztein, 
2006; Morimoto, 2008). A comparison of young and aging human retinas identified 
differential expression of a small number of genes involved in stress and immune 
response, protein and energy metabolism, and inflammation (Yoshida et al., 2002). 
According to another study, advanced age accounts for 30% of rod photoreceptor 
loss in the central macula (Curcio et al., 2000). Moreover, increasing amounts of 
A2E in lipofuscin as well as increasing thickness of BrM are also age-related ocular 
changes (Feeney-Burns and Ellersieck, 1985) that are potential triggers for AMD 
onset (Spraul et al., 1996). Although association of BrM thickness with AMD is 
debated (Chong et al., 2005), accumulation of lipoproteins has been found to be a 
significant age-related change (Curcio et al., 2001). 
 
INTRODUCTION 
 
11 | P a g e   
1.1.3.2. Environmental factors 
Like all multifactorial complex diseases, environmental factors play an important role 
in AMD development. There are increasing number of evidences where smoking has 
been consistently associated with AMD, leading to a two-fold or greater risk of 
developing the disease when compared to non-smokers (Vingerling et al., 1996; 
Age-Related Eye Disease Study Research, 2000; McCarty et al., 2001; Nakayama et 
al., 2014; Gopinath et al., 2015; Wu et al., 2015). The mechanism by which smoking 
affects the retina is unknown; it has been proposed that smoking may alter the 
metabolism of the RPE by interfering with antioxidants and altering choroidal blood 
flow (Hawkins et al., 1999). Another independent report also supports that smoking 
causes oxidative insults to the retina (Espinosa-Heidmann et al., 2006). 
 
Total fat intake was positively associated with risk of AMD, which may have been 
due to intake of individual fatty acids, such as linolenic acid, rather than to total fat 
intake per se (Cho et al., 2001). High fatty diet, obesity and other risk factors for 
cardiovascular diseases correlate with higher AMD susceptibility. Although the exact 
mechanism is not known, it is assumed that the contribution to AMD pathogenesis is 
related to increased oxidative stress, changes in the lipoprotein profile and increased 
inflammation resulting in increased cellular damage (Katta et al., 2009). Diet high in 
antioxidants lutein and zeaxanthin (found mostly in green leafy vegetables) and in 
omega-3 fatty acids (primarily found in fish) have been linked to a decreased risk of 
neovascular AMD (Flood et al., 2002; Seddon et al., 2003; Weikel et al., 2012). 
 
Apart from diet and smoking, there are additional environmental factors that may 
influence AMD pathogenesis, including sunlight exposure (Cruickshanks et al., 2001; 
Delcourt et al., 2001; Khan et al., 2006), alcohol use (Moss et al., 1998; Cho et al., 
2000; Chong et al., 2008) and infection by bacterial pathogens (particularly 
Chlamydia pneumoniae) (Kalayoglu et al., 2003; Baird et al., 2008). 
 
1.1.3.3. Race/ethnicity 
In 2006, an analysis of U.S. participants in the Multiethnic Study of Atherosclerosis 
(MESA) showed prevalence of AMD in persons aged 45 to 85 years to be 2.4% in 
African-Americans, 4.2% in Hispanics, 4.6% in Chinese-descent individuals and 
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5.4% in Caucasians (Klein et al., 2006). In a previous study by National Health and 
Nutritional Examination Survey it was observed that prevalence of AMD was 5.1% in 
Mexican-Americans, 7.3% in whites, and 2.4% in blacks (Klein et al., 1999b). These 
differences could be due to either environmental or genetic factors. It has been 
suggested that melanin may protect against the formation of lipofuscin (Weiter et al., 
1986). In 2013, an updated analysis of prevalence of AMD among multiethnic cohort 
revealed that early AMD was present in 4.0% of the cohort and varied from 2.4% in 
blacks to 6.0% in whites. However, common factors such as smoking, body mass 
index, inflammatory factors, diabetes and alcohol were unable to explain the 
significant difference in risk between whites and blacks (Klein et al., 2013). 
 
1.1.3.4. Genetic factors 
The genetic predisposition is a major risk factor for the development of AMD. 
Evidence for a genetic contribution is undebatable and comes from classical 
epidemiological and twin studies and gene-mapping studies (Heiba et al., 1994; 
Klein et al., 1994; Klaver et al., 1998). In the largest twin study published to date, it 
has been reported that 71% of AMD risk can be attributed to genetic influences 
(Seddon et al., 2005). 
 
1.1.3.4.1. The 1q31 locus 
In 2005, a pioneering genome-wide association study (GWAS) suggested 
complement factor H (CFH) gene on 1q31 as the first major AMD susceptibility gene 
(Fisher et al., 2005). Simultaneously, several studies have validated this result 
(Hageman et al., 2005; Haines et al., 2005; Klein et al., 2005; Zareparsi et al., 2005). 
Among more than 20 variants in and around the CFH gene, rs1061170 (c.1204C>T) 
accounts for an amino acid substitution (Y402H) in the CFH protein (Klein et al., 
2005). This synonymous single nucleotide polymorphism (SNP) lies within a 
haplotype conferring an increased risk for developing AMD by a factor of 2.5 in 
heterozygous carriers and by a factor of 6.2 in homozygous carriers (Conley et al., 
2006). Another common polymorphism in CFH, rs1410996 (c.2237-543G>A), was 
also discovered which, along with rs1061170, has been found to be liable for 17% of 
AMD susceptibility (Li et al., 2006; Maller et al., 2006; Raychaudhuri et al., 2011). 
Another rare non-synonymous variant, CFH (c.3628C>T), which accounts for an 
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amino acid substitution (R1210C), increases AMD risk by >20-fold and is virtually 
absent in the control individuals (1 heterozygous carrier in 2,268 sequenced 
controls) (Zhan et al., 2013). In addition to simple sequence changes, deletions in 
two genes near CFH, CFHR1 and CFHR3, have been associated with reduced risk 
of AMD (Hughes et al., 2006; Spencer et al., 2008).  
 
1.1.3.4.2. The 10q26 locus 
The second major AMD susceptibility locus is located on chromosome 10q26. The 
linkage to the genetic region at chromosomal segment 10q26 was first identified by 
(Weeks et al., 2000). In subsequent fine-mapping efforts designed to narrow the 
chromosome 10q26 linkage peak, the association signals were refined to three 
genes, namely, pleckstrin homology domain containing family A member 1 
(PLEKHA1), age-related maculopathy susceptibility 2 (ARMS2, also known as 
LOC387715) and high temperature requirement factor A1 (HTRA1) (Jakobsdottir et 
al., 2005). PLEKHA1 was later excluded as an AMD susceptibility gene (Rivera et 
al., 2005; Schmidt et al., 2006). As per the haplotype analysis done by Fritsche et al. 
(2008), the AMD-associated polymorphisms, that are fine-mapped on 10q26, 
continue on a 23.3 kb gene region. Overall, 15 AMD-associated polymorphisms were 
identified in this region (Figure 4), which are in a strong linkage disequilibrium (LD) 
to each other (Fritsche et al., 2008). 
 
Figure 4: Schematic overview of the AMD-associated 23.3 kb region on 
chromosome 10q26 exhibiting high linkage equilibrium. Stars indicate the 15 
AMD risk-associated polymorphisms; dark blue: ARMS2 exons 1 and 2; light blue: 
ARMS2 intron; white: intergenic region; dark red: HTRA1 exon 1; light red: HTRA1 
intron 1. Adapted from Friedrich et al. (2011). 
 
Further studies confirmed that all these polymorphisms occur together as an AMD-
associated risk haplotype (Yang et al., 2006; Wang et al., 2009; Wang et al., 2010b). 
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Eleven of these polymorphisms are intronic or intergenic, and two are synonymous 
SNPs in HTRA1 exon 1. The remaining two polymorphisms are located in the two 
exons of ARMS2. A non-synonymous SNP rs10490924 (c.205G>T) in the exon 1 of 
ARMS2 leads to an amino acid substitution in the ARMS2 protein at position 69 
(A69S), while EU427539 refers to a combination of a deletion and an insertion 
polymorphism within the 3' untranslated region (UTR) of the ARMS2 gene 
(*372_815delins54) (Fritsche et al., 2008). 
 
There are a number of contradictory reports about the effect of these polymorphisms 
on the functions of ARMS2 or HTRA1. The amino acid substitution caused by 
rs10490924 could bring a functional change in the ARMS2 protein (Wang et al., 
2009). The polymorphism EU427539, was shown to cause a destabilizing effect on 
the ARMS2 mRNA (Fritsche et al., 2008; Friedrich et al., 2011). However, other 
studies suggest that no effect of EU427539 polymorphism on the transcription of 
ARMS2 gene could be detected (Kanda et al., 2010; Wang et al., 2010b). Moreover, 
it has been shown that a common non-risk-associated non-synonymous variant, 
rs2736911 (c.112C>T), also leads to decreased ARMS2 transcript levels (Friedrich 
et al., 2011). Many contradictory reports were also shown either to have or not to 
have an influence of AMD-associated polymorphisms on expression of HTRA1. 
Some evidences show a two- to three-fold upregulation in HTRA1 expression due to 
the risk-associated polymorphisms (Yang et al., 2006; Chan et al., 2007; An et al., 
2010; Yang et al., 2010; Iejima et al., 2015). These results are consistent with a 
transgenic mouse model that ubiquitously overexpresses HTRA1 and exhibits 
characteristics similar to those of wet AMD patients (Jones et al., 2011). However, in 
other publications, no effect of AMD haplotypes was found on the HTRA1 expression 
level (Kanda et al., 2007; Chowers et al., 2008; Kanda et al., 2010; Wang et al., 
2010a; Friedrich et al., 2011; Wang et al., 2013). The effect of two AMD risk-
associated synonymous polymorphisms in exon 1 of the HTRA1, namely rs1049331 
(c.102C>T) and rs2293870 (c.108G>T), have been less studied because of the fact 
that they do not account for any amino acid change. A recent study by Jacobo et al. 
(2013) suggests that codon bias due to these synonymous polymorphisms results in 
difference in translation speed of the HTRA1 protein, which might affect its structure 
and function (Jacobo et al., 2013). 
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1.1.3.4.3. Other AMD-associated gene loci 
The recent meta-analysis of more than 17,100 AMD cases and more than 60,000 
control subjects of European and Asian origin reveals 19 loci from as many as 19 
chromosomes to be associated with AMD (Fritsche et al., 2013) (Figure 5). After 
identification of strong association of CFH with AMD, subsequent association studies 
showed additional complement genes to be strongly associated with AMD. These 
include complement 2 (C2) and/or complement factor B (CFB) (Gold et al., 2006), 
complement 3 (C3) (Yates et al., 2007) and complement factor I (CFI) (Fagerness et 
al., 2009). In AMD lesions, presence of immunomodulators suggests that local 
processes driven by complement dysregulation play a vital role in the development 
and progression of AMD (Johnson et al., 2000; Anderson et al., 2010).  
 
 
 
Figure 5: Nineteen common AMD risk variants in the discovery study of the 
AMD Gene Consortium meta-analysis. Summary of genome-wide association 
scan results in the discovery GWAS sample. Previously described loci before the 
meta-analysis reaching p < 5×10−8 are labeled in blue; newly found loci in the meta-
analysis reaching p < 5×10−8 for the first time after follow-up are labeled in green. 
Adapted and modified from Fritsche et al. (2013). 
 
Other than genes of complement system and genes on 10q26, functional analysis of 
a few other genes highly associated with AMD explains the development of AMD 
lesions. Hepatic lipase (LIPC) and cholesteryl ester transfer protein (CETP), found to 
be associated with AMD, are expressed in the subretinal space and may participate 
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in rapid cholesterol transfer from the RPE to the neural retina (Tserentsoodol et al., 
2006a; Tserentsoodol et al., 2006b). Apolipoprotein E (ApoE) has also been 
detected in subretinal lesions where it promotes chronic inflammation in AMD (Levy 
et al., 2015). Tissue inhibitor of metalloprotienase 3 (TIMP3) has been found to play 
a pivotal role in ECM maintenance and remodeling in BrM (Fariss et al., 1997; Kamei 
and Hollyfield, 1999). Apart from this, seven previously unknown loci discovered in 
the meta-analysis are COL8A1-FILIP1L, IER3-DDR1, SLC16A8, TGFBR1, RAD51B, 
ADAMTS9 and B3GALTL. Though weakly associated with the disease, functional 
analysis of these genes might lead to a clear idea of AMD pathogenesis. 
 
1.2. HTRA1 protein 
The HTRA family of proteins is broadly characterized by a highly conserved protease 
domain and one or more C-terminal protein-interaction domains (Singh et al., 2011; 
Malet et al., 2012). The first described member of HTRA family, the Escherichia coli 
(E.coli) HtrA protein (also called DegP or protease Do) is a periplasmic protein 
(Clausen et al., 2002) that is upregulated under stress conditions such as heat shock 
(Lipinska et al., 1988; Lipinska et al., 1989). HtrA functions as a chaperone and a 
protease in a temperature-dependent fashion (Spiess et al., 1999).  
1.2.1. Structure of HTRA1 
 
 
Figure 6: Structure of HTRA1. Boxes represent protein domains; blue box indicates 
S, signal peptide domain cleaved in mature secreted protein; purple box indicates 
MAC25/IGFBP(insulin growth factor–binding protein) domain; yellow box indicates 
Kazal-like domain (KI); green box indicates serine protease domain, which contains 
Histidine (H), Aspargine (D) and Serine (S) forming a catalytic triad; red box 
indicates PDZ [postsynaptic density protein (psd95), drosophila disc large tumor 
suppressor (dlga), and zonula occludens-1 protein (zo-1) domain]. Adapted from An 
et al. (2010). 
 
HTRA1, a secreted protease was first identified in 1996 as a gene expressed in 
human fibroblast cells (Zumbrunn and Trueb, 1997). The degree of conservation 
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between human HTRA1 and its bacterial homologues DegP is very high (Clausen et 
al., 2002). Human HTRA1 is one of the four members of the human HTRA family 
and consists of 480 amino acids (about 50 kDa), which are encoded by the nine 
exons of the HTRA1 gene. Figure 6 depicts the structure of HTRA1. It has an N-
terminal signal peptide (S) for secretion. After secretion, a 22 amino acid-long signal 
peptide of the HTRA1 protein is cleaved. The MAC25 domain has a homology to the 
insulin like growth factor binding protein (IGFBP) and follistatin. Although the MAC25 
domain showed homology initially to IGFBP, later it turned out that it has obvious 
lower affinity for the insulin like growth factor (IGF) than other IGFBPs (Eigenbrot et 
al., 2012). The homology to follistatin, however, led to the discovery that the MAC25 
domain of HTRA1 protein can bind to activin, a member of transforming growth 
factor-β (TGF-β) superfamily (Oka et al., 2004). Kazal inhibitors, specifically inhibit 
serine proteases like trypsin and elastase (Rawlings et al., 2004). The largest 
domain of HTRA1 is the protease domain with the catalytic triad of histidine (His220), 
asparagine (Asp250) and serine (Ser328), which defines HTRA1 as serine protease 
(Figure 6). By C-terminal protein interaction domain named “postsynaptic density 
protein (psd95), drosophila disc large tumor suppressor (dlga), and zonula 
occludens-1 protein (zo-1) domain” (PDZ), HTRA1 binds to its substrates.  
 
 
 
Figure 7: Three-dimensional structure of HTRA1 trimer. Ribbon presentation of 
HTRA1 (inactive structure) in (A) top and (B) side views. The individual monomers 
are shown in different colors. Adapted and modified from Truebestein et al.(2011). 
 
HTRA1 forms a trimeric structure which is mediated by N-terminal amino acid 
residues of the protease domain (Figure 7) (Truebestein et al., 2011). The protein 
interaction domain (PDZ) binds sequence-specifically to short C-terminal or internal 
hydrophobic sequences of peptides. In this case, the PDZ domains of the members 
of HTRA family are different, when it comes to ligand specificity. Previously, it was 
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assumed that the PDZ domain of HTRA1 negatively regulates the proteolytic activity. 
Thus, the protease activity is to be activated only when the PDZ domain binds to the 
ligands (Murwantoko et al., 2004). However, based on the latest study of the crystal 
structure of HTRA1 trimers, the research groups of Tim Clausen and Michael 
Ehrmann showed that PDZ domain is not indespensible for the protease activity. 
Instead substrate binding to the active site is sufficient to stimulate protease activity 
(Truebestein et al., 2011). Accordingly, no allosteric ligands would be necessary for 
the activation of HTRA1 as opposed to activation of bacterial HtrA. 
1.2.2. Function of HTRA1 
HTRA1 was reported to influence cell signaling (Oka et al., 2004; Zhang et al., 2012; 
Graham et al., 2013; Supanji et al., 2013), organization of the ECM (Mauney et al., 
2010; Vierkotten et al., 2011), embryogenesis (De Luca et al., 2004) and skeletal 
development and osteogenesis (Tsuchiya et al., 2005; Hadfield et al., 2008). Various 
publications have identified an array of interaction partners of HTRA1 such as 
members of TGF-β family (BMP3, GDF5, activin, TGF-βs) (Oka et al., 2004); 
aggrecan, biglycan, decorin, fibromodulin, fibronectin, soluble type II collagen and 
elastin (Tsuchiya et al., 2005); mature TGF-β1 (Launay et al., 2008); tubulin (Chien 
et al., 2009); tuberous sclerosic complex 2 (Campioni et al., 2010); clusterin, 
vitronectin, fibromodulin, alpha-2 macroglobulin and ADAM9 (An et al., 2010); 
fibronectin, fibulin 5 and nidogen 1 (Vierkotten et al., 2011); pro-TGF-β1 (Shiga et 
al., 2011); IGF-1(Jacobo et al., 2013); and TGF-β receptors II and III (Graham et al., 
2013). In addition, HTRA1 was suggested to influence the pathogenic processes of 
several diseases including CARASIL (cerebral autosomal recessive arteriopathy with 
subcortical infarcts and leukoencephalopathy) (Hara et al., 2009; Shiga et al., 2011), 
osteoarthritic cartilage (Grau et al., 2006; Chamberland et al., 2009; Polur et al., 
2010), preeclampsia (Ajayi et al., 2008) and AMD (Vierkotten et al., 2011; Zhang et 
al., 2012; Nakayama et al., 2014). HTRA1 may also exhibit tumor suppressor 
activities (Baldi et al., 2002; De Luca et al., 2003; Chien et al., 2004), as 
downregulation of the protein was observed in a variety of cancers, e.g., 
endometrial, ovarian or breast cancers, and melanomas (Baldi et al., 2002; Shridhar 
et al., 2002; Chien et al., 2004; Bowden et al., 2006; Mullany et al., 2011; Wang et 
al., 2012). Despite its suspected role in the various disease processes, the exact 
mechanisms of HTRA1 are largely unknown. 
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2. AIM OF THE STUDY 
 
Several polymorphisms in HTRA1 located in chromosomes 10q26 have been 
reported to be associated with AMD by various independent studies (Dewan et al., 
2006; Fritsche et al., 2013). Recently, two synonymous polymorphisms have been 
found to have effect on the translational efficiency of HTRA1 and its binding capacity 
of IGF-1 (Jacobo et al., 2013). The focus of our study was set on unraveling the 
effect of AMD-associated synonymous SNPs rs1049331 (c.102C>T) and rs2293870 
(c.108G>T) within exon 1 of HTRA1 on the conformation, secretion and substrate 
affinity of HTRA1 protein. In several studies, HTRA1 has been shown to inhibit TGF-β 
signaling (Oka et al., 2004; Launay et al., 2008; Shiga et al., 2011; Zhang et al., 
2012; Graham et al., 2013; Karring et al., 2013). So, the aim also included the 
influence of synonymous polymorphisms on regulation of intracellular TGF-β 
signaling. The final aim was to investigate the effect of HTRA1 on activation of 
microglial cells. 
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3. MATERIALS AND METHODS 
3.1. Materials 
3.1.1. Chemicals and reagents 
Table 2: Chemicals and reagents 
Chemical/reagent Supplier 
2-Nitrophenyl β-D-galactopyranoside 
(ONPG) 
Sigma-Aldrich, St. Louis, MO, USA 
2-Propanol Merck Chemicals GmbH, Schwalbach, 
Germany 
4',6-diamidino-2-phenylindole (DAPI) Merck Chemicals GmbH, Schwalbach, 
Germany 
5-Bromo-4-chloro-3-indolyl β-D-
galactopyranoside (X-Gal) 
AppliChem GmbH, Darmstadt, Germany 
β-casein from bovine milk  Sigma-Aldrich, St. Louis, MO, USA 
β-Mercaptoethanol Sigma-Aldrich, St. Louis, MO, USA 
Acetic Acid (100%) Merck Chemicals GmbH, Schwalbach, 
Germany 
Albumin fraction V (BSA) AppliChem GmbH, Darmstadt, Germany 
Ammonium persulfate (APS) AppliChem GmbH, Darmstadt, Germany 
Agarose (Byozyme LE) Biozym Scientific GmbH, Hessisch 
Oldendorf, Germany 
Ampicillin  Carl Roth GmbH, Karlsruhe, Germany 
Bacto™ Agar Becton, Dickinson and Company, Franklin 
Lakes, USA  
Bacto™ Yeast Extract Becton, Dickinson and Company, Franklin 
Lakes, USA  
Boric acid (H3BO3) Merck Chemicals GmbH, Schwalbach, 
Germany 
Bromphenol blue Sigma-Aldrich, St. Louis, MO, USA 
Casein from Bovine Milk Merck Chemicals GmbH, Schwalbach, 
Germany 
Coomassie Billiant Blue (Thermo Scientific) VWR International, 
Germany 
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Chemical/reagent Supplier 
Developer solution AGFA, Mortsel, Belgium 
Dimethyl sulfoxide (DMSO) Merck Chemicals GmbH, Schwalbach, 
Germany 
Ethanol J.T. Baker, Phillipsburg, USA 
Ethanol ≥99,8 p.a Carl Roth GmbH, Karlsruhe, Deutschland 
Ethidium bromide AppliChem GmbH, Darmstadt, Germany 
Ethylenediaminetetraacetic acid 
(EDTA) 
(Titriplex) Merck Chemicals GmbH, 
Schwalbach, Germany 
FlAsH-EDT2  Invitrogen, Carlsbad, CA, USA 
Fixer solution AGFA, Mortsel, Belgium 
Glycerol AppliChem GmbH, Darmstadt, Germany 
Hi-Di™ Formamide Applied Biosystems Inc., Foster City, USA 
HTRA1(His-tagged) ProteaImmun GmbH, Berlin, Germany 
Hydrogen chloride (HCl) Merck Chemicals GmbH, Schwalbach, 
Germany 
Hydrogen peroxide Merck Chemicals GmbH, Schwalbach, 
Germany 
Isopropyl β-D-1-
thiogalactopyranoside (IPTG) 
AppliChem GmbH, Darmstadt, Germany 
Luminol Sigma-Aldrich, St. Louis, MO, USA 
Methanol Merck Chemicals GmbH, Schwalbach, 
Germany 
Milk powder Carl Roth GmbH, Karlsruhe, Germany 
p-Coumarin acid Sigma-Aldrich, St. Louis, MO, USA 
Paraformaldehyde (PFA) Merck Chemicals GmbH, Schwalbach, 
Germany 
Phenylmethanesulfonylfluoride 
(PMSF) 
Merck Chemicals GmbH, Schwalbach, 
Germany 
Roti® Quant Carl Roth GmbH, Karlsruhe, Germany 
Rotiphorese Gel 40 (29:1) 
acrylamide/bisacrylamide 
Carl Roth GmbH, Karlsruhe, Germany 
Sodium acetate, trihydrate  AppliChem GmbH, Darmstadt, Germany 
Sodium carbonate (Na2CO3) Merck Chemicals GmbH, Schwalbach, 
Germany 
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Chemical/reagent Supplier 
Sodium chloride (NaCl) VWR International, LLC, West Chester, 
USA 
Sodium hydroxide (NaOH) Merck Chemicals GmbH, Schwalbach, 
Germany 
Sodium dodecyl sulfate (SDS) Carl Roth GmbH, Karlsruhe, Germany 
Sodium hydrogen carbonate 
(NaHCO3) 
AppliChem GmbH, Darmstadt, Germany 
TCEP HCl Thermo Fisher Scientific, Hudson, USA 
Tetramethylethylenediamine 
(TEMED) 
AppliChem GmbH, Darmstadt, Germany 
Tris(hydroxymethyl)aminomethane 
(Tris) 
Merck Chemicals GmbH, Schwalbach, 
Germany 
Trypsin EDTA in 10X Buffer PAA Laboratories GmbH, Parsching, 
Austria 
TPCK-trypsin Sigma-Aldrich, St. Louis, MO, USA 
Tryptone/Peptone from casein Carl Roth GmbH, Karlsruhe, Germany 
Xylene cyanol Sigma-Aldrich, St. Louis, MO, USA 
X-gal (5-bromo-4-chloro-3-indolyl-β-
D-galactopyranoside) 
AppliChem GmbH, Darmstadt, Germany 
Recombinant TGF-β1 PeproTech, Hamburg, Germany 
Recombinant interleukin 4 (IL4) PeproTech, Hamburg, Germany 
Lipopolysaccharide (LPS) from E.coli  Sigma-Aldrich, St. Louis, MO, USA 
 
3.1.2. Kits and ready-made solutions 
Table 3: Kits and ready-made solutions 
Kit/solution Supplier Application 
10X ThermoPol 
Reaction Buffer 
New England BioLabs® Inc., 
Ipswich, USA 
A-tailing of PCR 
products 
5X GoTaq® Reaction 
Buffer Kit 
Promega Corporation, Madison, 
USA 
PCR 
Griess Reagent System Promega Corporation, Madison, 
USA 
Nitrite 
measurement 
AccuPrime™ Taq 
Polymerase PCR 
Life Technologies, Carlsbad, CA, 
USA 
PCR 
MATERIALS AND METHODS 
 
23 | P a g e   
Kit/solution Supplier Application 
BigDye® Terminator v1.1 
Cycle Sequencing Kit 
Applied Biosystems Inc., Foster 
City, USA 
Cycle sequencing 
dNTP-Set Genaxxon BioScience GmbH, Ulm, 
Germany 
PCR, cDNA 
synthesis 
Luciferase Assay 
Reagent 
Promega Corporation, Madison, 
USA 
Luciferase assay 
NEBuffer CutSmart®  New England BioLabs® Inc., 
Ipswich, USA 
Restriction 
digestion 
NucleoBond® Xtra Midi MACHEREY-NAGEL GmbH & Co. 
KG, Düren, Germany 
Plasmid isolation 
NucleoSpin® Extract II MACHEREY-NAGEL GmbH & Co. 
KG, Düren, Germany 
Gel extraction of 
DNA fragments 
NucleoSpin® Plasmid MACHEREY-NAGEL GmbH & Co. 
KG, Düren, Germany 
Plasmid isolation 
GeneRuler™ DNA 
Ladder Mix 
Fermentas International Inc., 
Burlington, Canada 
Marker for DNA 
electrophoresis 
PageRuler™ 
Prestained Protein 
Ladder 
Fermentas International Inc., 
Burlington, Canada 
Marker for protein 
electrophoresis 
pGEM®-T Vector 
System 
Promega Corporation, Madison, 
USA 
Subcloning 
Reporter Lysis 5X Buffer Promega Corporation, Madison, 
USA 
Luciferase assay 
RevertAid™ 5X 
Reaction Buffer 
Fermentas International Inc., 
Burlington, Canada 
cDNA synthesis 
RNAlater® Applied Biosystems/Ambion, 
Austin, USA 
RNA purification 
RNase-Free DNase Set Qiagen N.V., Hilden, Germany RNA purification 
RNeasy® Mini Kit Qiagen N.V., Hilden, Germany RNA purification 
SuperSignal West 
Femto Maximum 
Sensitivity Substrate 
Thermo Fisher Scientific, Hudson, 
USA 
Immunoblot: protein 
detection by 
chemiluminescence 
T4 DNA Ligase 
Reaction Buffer (10X) 
New England BioLabs® Inc., 
Ipswich, USA 
Ligation 
Taq buffer 15 mM 
MgCl2 (10X) 
New England BioLabs® Inc., 
Ipswich, USA 
PCR 
TaqMan® Gene 
Expression Master Mix 
Applied Biosystems Inc., Foster 
City, USA 
qRT-PCR 
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Kit/solution Supplier Application 
TC-FlAsH™ II In-Cell 
Tetracysteine Tag 
Detection (Green 
Fluorescence) 
Invitrogen, Carlsbad, CA, USA MicroScale 
Thermophoresis 
TransIT®-LT1 
Transfection Reagent 
Mirus Bio LLC, Madison, USA Transfection 
SuperSignal West 
Femto Maximum 
Sensitivity Substrate 
VWR International Germany 
GmbH, Darmstadt, Germany 
Western blot 
Twin-Strep® Kit IBA GmbH, Göttingen, Germany Recombinant 
protein purification 
 
3.1.3. Buffers and solutions 
Table 4: Buffers and solutions 
Buffer Chemical Composition Percentage Composition 
Blocking solution Milk powder 
1X PBS or 1XPBST 
3% (w/v) 
Coomassie stainer Methanol 
Acetic acid 
Coomassie Brilliant Blue 
30% 
10% 
0.10% w/v 
Coomassie 
destainer 
Methanol 
Acetic acid 
30% 
10% 
DNA-loading buffer 
(10X) 
Tris-HCl pH 7.5,  
Sodium acetate, 
EDTA, 
Glycine,  
Bromphenol blue 
Xylene cyanol 
10 mM 
5 mM 
2 mM 
10% v/v 
0.001% v/v 
0.001% v/v 
ECL solution 1 Luminol 
0.1 M Tris-HCl 
50 mg 
200 ml 
ECL solution 2 p-Coumarin acid 
DMSO 
0.0011% 
Laemmli buffer Tris-HCl pH 6.8, 
Glycerine  
β-mercaptoethanol  
SDS 
Bromphenol blue 
195 mM 
30% 
10% 
6% 
0.75% 
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Buffer Chemical Composition Percentage Composition 
PBS (10X) NaCl 
Na2HPO4  
KCl  
KH2PO4, pH 7.4 
1.37 M 
100 mM 
27 mM 
18 mM 
SDS-running buffer 
(10X) 
Tris-HCl 
Glycine  
SDS, pH 8.6 
25 M 
2 M 
10% (w/v) 
Digestion buffer pH 
7.5 
Tris-HCl 
NaCl 
CaCl2 
50 mM 
150 mM 
5 mM 
Casein solution Casein from bovine milk 
Digestion buffer pH 7.5 
0.02% 
TBE (5X) Tris-HCl,  
H3BO3,  
EDTA, pH 7.4 
0.5 M 
0.5 M 
10 mM 
TE buffer Tris-HCl  
EDTA, pH 7.5 or pH 8.0 
10 mM 
1 mM 
TRIS buffer saline Tris-HCl [pH 8.0],  
NaCl  
150 mM 
100 mM 
Towbin transfer 
buffer 
Tris-HCl  
Glycine 
Methanol 
0.025 M 
0.192 M 
20% 
Twin-Strep® Elution 
Buffer (Buffer E) 
Tris-HCl pH 8 
NaCl 
EDTA 
Desthiobiotin 
100 mM 
150 mM 
1 mM 
2.5 mM 
Twin-Strep® 
Regeneration Buffer 
(Buffer R) 
Tris-HCl pH 8 
NaCl 
EDTA 
HABA 
100 mM 
150 mM 
1 mM 
1 mM 
Twin-Strep® Wash 
Buffer (Buffer W) 
NaCl 
EDTA 
Tris-HCl pH 8 
150 mM 
1 mM 
100 mM 
X-Gal solution X-Gal 
DMSO 
0.04% w/v 
Xylene cyanol Xylene cyanol 
Glycerin (87%) 
H2O dest. 
0.1% v/v 
40% v/v 
Ad. 50 ml 
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3.1.4. Cell lines 
3.1.4.1. Bacterial cells 
Table 5: E.coli strains 
Strain Genotype Reference/Origin 
E.coli 
strain 
DH5α 
fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 
Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 
hsdR17 
Life Technologies, 
Carlsbad, CA, USA 
E.coli 
strain 
JM110 
rpsL (Strr) thr leu thi-1 lacY galK galT ara tonA 
tsx dam dcm supE44 ∆(lac-proAB) [F´ traD36 
proAB lacIq Z∆M15]. 
Life Technologies, 
Carlsbad, CA, USA 
  
3.1.4.2 Mammalian cell lines 
Table 6: Mammalian cell lines 
Cell line Origin Culture  
Hek293-Ebna 
cells 
Human embryonic kidney 
cells 
Invitrogen, Carlsbad, CA, USA 
MLEC-PAI/Luc 
cells 
Mouse lung epithelial cells 
(MLEC) stably transfected 
with an expression construct 
containing a truncated PAI-1 
promoter fused to the firefly 
luciferase reporter gene 
ATCC, Manassas, VA, USA 
BV-2 Mouse microglia cells  Kindly provided by Prof. 
Thomas Langmann, 
Department of Ophthalmology, 
University of Cologne, 
Germany 
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3.1.4.3. Media and supplements 
Table 7: Cell culture media and supplements 
Cell culture medium Suppliers 
DMEM High Glucose (4.5 g/l) with L-
Glutamine 
(Gibco) Life Technologies GmbH, 
Darmstadt, Germany 
Fetal Bovine Serum Gold (FBS) (Gibco) Life Technologies 
GmbH, Darmstadt, Germany 
Opti-MEM® I Reduced Serum Media (Gibco) Life Technologies GmbH, 
Darmstadt, Germany 
Genticin Sulphate (G418) Solution (PAA) GE Healthcare, Galfont St 
Giles, United Kingdom 
Penicillin/Streptomycin/L-Glutamine (PAA) GE Healthcare, Galfont St 
Giles, United Kingdom 
RPMI 1640 without L-Glutamine (PAA) GE Healthcare, Galfont St 
Giles, United Kingdom 
Dulbecco’s 10X PBS (Gibco) Life Technologies GmbH, 
Darmstadt, Germany 
 
Table 8: Medium for cultivation of E.coli 
Medium Composition 
LB medium 1% NaCl, 1% Tryptone/Peptone from casein, 0.5% Bacto™ 
Yeast Extract  
 
LB medium for cultivation of E.coli was sterilized by autoclaving and stored at 4°C. 
For casting of plates, 1.5% Bacto™ Agar were added to the medium prior to 
autoclaving. If needed, autoclaved medium was supplemented with 100 µg/ml 
ampicillin (LBAmp). 
3.1.5. Enzymes 
Table 9: Enzymes 
Enzyme Supplier Application 
AccuPrime™ Taq 
Polymerase 
Life Technologies, Carlsbad, CA, USA PCR 
XhoI New England BioLabs® Inc., Ipswich, 
USA 
Restriction 
digestion 
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Enzyme Supplier Application 
BseRI New England BioLabs® Inc., Ipswich, 
USA 
Restriction 
digestion 
FseI New England BioLabs® Inc., Ipswich, 
USA 
Restriction 
digestion 
NotI-HF™ New England BioLabs® Inc., Ipswich, 
USA 
Restriction 
digestion 
DpnI New England BioLabs® Inc., Ipswich, 
USA 
Methylated 
sequence cutter 
PfuUltra HF DNA 
polymerase 
Agilent Technologies, CA, USA PCR 
Proteinase K Merck KGaA, Darmstadt, Germany DNA isolation 
RevertAid™ M-
MuLV Reverse 
Transcriptase 
Fermentas International Inc., 
Burlington, Canada 
cDNA synthesis 
T4 DNA Ligase New England BioLabs® Inc., Ipswich, 
USA 
Ligation 
Taq DNA 
Polymerase 
New England BioLabs® Inc., Ipswich, 
USA 
A-tailing of PCR 
products 
 
3.1.6. Antibodies 
Table 10: Primary antibodies (mAB: monoclonal antibody; pAB: polyclonal 
antibody; WB: Western blot) 
Antibody Type Species Dilution Use Reference 
HTRA-1 (AB 
65902) 
pAB Rabbit 1:2000 WB abcam, Cambridge, 
United Kingdom 
β-
actin(ACTB) 
mAB Mouse 1:10,000 WB Sigma-Aldrich, St. Louis, 
MO, USA 
TGF-β1(SC-
146) 
pAB Rabbit 1:10,000 WB Santa 
CruzBiotechnology, Inc., 
Dallas, TX, USA 
SMAD-2 pAB Rabbit 1:1000 WB Cell Signaling 
Technology, Beverly, MA, 
USA 
pSMAD-2 pAB Rabbit 1:1000 WB Cell Signaling 
Technology, Beverly, MA, 
USA 
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Table 11: Secondary antibodies 
Antibody Supplier Application 
Goat anti-mouse IgG, 
peroxidase conjugate 
(Calbiochem) Merck Chemicals 
GmbH, Schwalbach, Germany 
WB 
Goat anti-rabbit IgG, 
peroxidase conjugate 
(Calbiochem) Merck Chemicals 
GmbH, Schwalbach, Germany 
WB 
 
3.1.7. Vectors and plasmids 
Table 12: Starting vectors 
Vector Supplier 
pCEP4 Invitrogen™, Carlsbad, USA 
pGEM®-T Vector Promega Corporation, Madison, USA 
pEXPR-IBA103 IBA GMBH, Göttingen, Germany 
 
Table 13: Control plasmids and plasmids with insert already available 
Plasmid Supplier 
“pGEM®-T + HTRA1 mRNA 
non-risk” (pGEM®-T construct 
for HTRA1:CG variant) 
Institute of Human Genetics, University Hospital 
Regensburg, Regensburg, Germany 
“pCEP4 + HTRA1 mRNA non-
risk” (pCEP4 construct for 
HTRA1:CG variant) 
Institute of Human Genetics, University Hospital 
Regensburg, Regensburg, Germany 
“pCEP4 + HTRA1 mRNA risk” 
(pCEP4 construct for HTRA1:TT 
variant) 
Institute of Human Genetics, University Hospital 
Regensburg, Regensburg, Germany 
“pEXPR-IBA103 + HTRA1 
mRNA non-risk” (pEXPR-
IBA103 construct for HTRA1:CG 
variant) 
Institute of Human Genetics, University Hospital 
Regensburg, Regensburg, Germany 
“pEXPR-IBA103 + HTRA1 
mRNA risk” (pEXPR-IBA103 
construct for HTRA1:CG variant) 
Institute of Human Genetics, University Hospital 
Regensburg, Regensburg, Germany 
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3.1.8. Oligonucleotides 
The following oligonucleotides were used as primers and were supplied by Metabion 
International AG (Martinsried, Germany).  
Table 14: Sequence and use of oligonucleotides for PCR in the study  
Primer Name  Sequence 5’-3’ Use 
Htra1- endoBseRI-
F 
CAAAATTGACCACCAGGGCAAG
C 
Cloning TC-tagged 
HTRA1:CG or 
HTRA1:TT in pCEP4 
vector  
Htra1-TCtag-R GCAACAGCCAGGACAACATGGG
TCAATTTCTTCGGGAATCACTGT
GAT 
Cloning TC-tagged 
HTRA1:CG in pCEP4 
vector 
Htra1-TCtag-R2 AAGAAATTGACCCATGTTGTCCT
GGCTGTTGCTAGCTCGAG 
Cloning TC-tagged 
HTRA1:CG or 
HTRA1:TT in pCEP4 
vector 
Htra1-TCtag-R2 
(rev. comp.) 
CTCGAGCTAGCAACAGCCAGGA
CAACATGGGTCAATTTCTT 
Cloning TC-tagged 
HTRA1:CG or 
HTRA1:TT in pCEP4 
vector 
Htra1-mRNA-NotI-
F 
GCGGCCGCGCGCACTCGCACCC
GCT 
Cloning TC-tagged 
HTRA1:TT in pCEP4 
vector 
Htra1-RT-R2 GATGGCGACCACGAACTC Cloning TC-tagged 
HTRA1:TT in pCEP4 
vector 
HTRA1_SN_MUT
_F 
GCAGCGGTCTGGGCACCCGGC
GGCCAAAGGC 
Cloning TC-tagged 
HTRA1:CC in pCEP4 
vector  
HTRA1_SN_MUT
_R 
GCCTTTGGCCGCCGGGTGCCCA
GACCGCTGC 
Cloning TC-tagged 
HTRA1:CC in pCEP4 
vector 
HTRA1-RT-F2 AGCAGACATCGCACTCATCA Sequencing of HTRA1 
constructs 
HTRA-Ex1-F0 AGGCCCTCCTGCACTCT Sequencing of HTRA1 
constructs 
HTRA1-Ex1-R2 CGCCGCACGGGCCCTCC Sequencing of HTRA1 
constructs 
HTRA1-Ex2-R GCCATCTTCCCACCACGT Sequencing of HTRA1 
constructs 
MATERIALS AND METHODS 
 
31 | P a g e   
Primer Name  Sequence 5’-3’ Use 
HTRA1-Ex1-F AGAGCGCCATGCAGATCC Sequencing of HTRA1 
constructs 
pEXPR-IBA103-F GAGAACCCACTGCTTACTGGC Sequencing of Strep-
tagged constructs 
pEXPR-IBA103-R TAGAAGGCACAGTCGAGG Sequencing of Strep-
tagged constructs 
M13-F CACGACGTTGTAAAACGAC Sequencing of pGEM®-
T constructs 
M13-R GGATAACAATTTCACACAGG Sequencing of pGEM®-
T constructs 
 
Table 15: Primers for first strand cDNA synthesis 
Name Supplier 
Random hexamer primer Fermentas International Inc., Burlington, Canada 
 
Table 16: Probes and oligonucleotides used for qRT-PCR 
Gene Primer Name Sequence Roche 
Probe # 
Arg1 mARG1_RT_F1 GAATCTGCATGGGCAACC 2 
mARG1_RT_R1 GAATCCTGGTACATCTGGGAAC 
Ym1 mYM1-RT-F3 AAGACACTGAGCTAAAAACTCTCC 88 
mYM1-RT-R3 GAGACCATGGCACTGAACG 
IL6 mIL6-RT-F CCAGGTAGCTATGGTACTCCAGA 6 
mIL6-RT-R GATGGATGCTACCAAACTGGAT 
iNOS mINOS-RT-F CTTTGCCACGGACGAGAC 3 
mINOS-RT-R TCATTGTACTCTGAGGGCTGA 
Mouse 
ATPase 
mATPase-RT-F CAGCAGATTTTAGCAGGTGAA 77 
mATPase-RT-R CTGCCAGCTTATCAGCCTTT 
 
MATERIALS AND METHODS 
 
32 | P a g e   
3.1.9. Consumables 
Table 17: Consumables 
Consumable Supplier 
96-well Plate Applied Biosystems Inc., Foster City, USA 
Amicon Ultra 10,000 Kw 4 ml 
columns  
Merck, Millipore, Billercia, MA, USA 
Cell culture dishes: 100 mm x 
20 mm style 
Sarstedt AG & Co., Nümbrecht, Germany 
Cell culture plates: 12-well Corning Incorporated, Corning, USA 
Cell culture plates: Costar 6-
well  
Corning Incorporated, Corning, USA 
Cell scraper 30 cm Orange Scientific, Braine-l'Alleud, Belgium 
Disposable gloves: Blue VWR International Germany GmbH, Darmstadt, 
Germany 
Disposable gloves: Green Kimberly-Clark Professional, Roswell, GA, USA 
Disposable scalpels  Feather Safety Razor Co., Ltd., Osaka, Japan 
Falcon tubes (15, 50 ml)  Sarstedt AG, Nürnbrecht, Germany 
Forceps: Dumont #5 Fine Science Tools GmbH, Heidelberg, Germany 
Insulin syringes: BD Micro-
Fine™+ 0.5 ml 0.33 mm (29G) 
x 12.7 mm U-100 
Becton, Dickinson and Company, Franklin Lakes, 
USA 
Magnetic stir bars Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
Micro tubes: SafeSeal Micro 
Tubes  
Sarstedt AG, Nürnbrecht, Germany 
Microplate: LUMITRAC™ 200 Greiner Bio-One GmbH, Frickenhausen, Germany 
PCR stripes: PCR SoftStrips Biozym Scientific GmbH, Oldendorf, Germany 
Pipette filter tips: SafeSeal-Tips 
Professional 
Biozym Scientific GmbH, Oldendorf, Germany 
Pipette tips (10,100, 1000 µl) VWR International Germany GmbH, Darmstadt, 
Germany 
Pipette tips (qRT-PCR): 30 µl 
(384 tips) 
Thermo Fisher Scientific, Hudson, USA 
Plastic weighing trays VWR International Germany GmbH, Germany 
PVDF transfer membrane: 
Immobilon-P  
Millipore Corporation, Billerica, USA 
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Consumable Supplier 
qRT-PCR plates: MicroAmp 
Optical 384-Well Reaction Plate 
Applied Biosystems Inc., Foster City, USA 
Scissors: HB 7459  HEBUmedical GmbH, Tuttlingen, Germany 
Scissors: Vannas-Tübingen 
Spring Scissors - 5mm Blades 
Fine Science Tools GmbH, Heidelberg, Germany 
Standard Capillaries NanoTemper Technologies, Munich, Germany 
Standard Cuvettes Sarstedt AG, Nürnbrecht, Germany 
Syringe needles: Microlance 3 
20G 
Becton, Dickinson and Company, Franklin Lakes, 
USA 
Syringes: Plastipak 1 ml Becton, Dickinson and Company, Franklin Lakes, 
USA 
Tissue culture flasks: 175 cm2 
(vented cap) 
Becton, Dickinson and Company, Franklin Lakes, 
USA 
Tissue culture flasks: 25 cm2 
(filter cap) 
TPP AG, Trasadingen, Switzerland 
Tissue culture flasks: 75 cm2 (PE 
vented cap) 
Sarstedt AG, Nürnbrecht, Germany 
Whatman Paper: 3M Chr  Whatman plc, Maidstone, UK 
X-ray film: CRONEX™ 5 
(13x18) 
Agfa-Gevaert N.V., Mortsel, Belgium 
 
3.1.10. Instruments 
Table 18: Instruments 
Instrument Name Supplier 
Automated sample 
disruption 
TissueLyser Qiagen N.V., Hilden, Germany 
Balance SBC52 Scaltec Instruments GmbH, Göttingen, 
Germany 
Capillary sequencer 3130xl Genetic 
Analyzer 
Applied Biosystems Inc., Foster City, 
USA 
Centrifuge (for cell 
culture) 
5810 Eppendorf AG, Hamburg, Germany 
Tabletop centrifuge Biofuge fresco Heraeus Holding GmbH, Hanau, 
Germany 
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Instrument Name Supplier 
Cold Falcon 
centrifuge 
Megafuge 1.0R Heraeus Holding GmbH, Hanau, 
Germany 
Falcon centrifuge Megafuge 3L Heraeus Holding GmbH, Hanau, 
Germany 
Clean bench (for 
bacteria)  
Hera guard HPA 
12/65 
Thermo Fisher Scientific, Hudson, USA 
Dark Hood DH-40 biostep GmbH, Jahnsdorf, Germany 
Dark Hood (printer) P93D Mitsubishi Electric Corporation, Tokyo, 
Japan 
DNA electrophoresis 
system 
BlueMarine 200 Serva Electrophoresis GmbH, 
Heidelberg, Germany 
Flake-ice machine AF100 Scotsman Ice Systems, Vernon Hills, 
USA 
Fluorescence 
microscope  
Axioskop 2 mot 
plus 
Carl Zeiss GmbH, Jena, Germany 
Fluorescence 
microscope (camera) 
AxioCam MRc Carl Zeiss GmbH, Jena, Germany 
Fluorescence 
microscope (light-
source) 
FluoArc Carl Zeiss GmbH, Jena, Germany 
Image scanner Fujifilm FLA-
5000 
 Fujifilm, Düsseldorf, Germany 
Incubation hood Certomat® HK B. Braun Biotech International GmbH, 
Melsungen, Germany 
Incubator (for 
bacteria) 
INB 400 Memmert GmbH + Co. KG, Schwabach, 
Germany 
Incubator (for cell 
culture) 
CB 210 Binder GmbH, Tuttlingen, 
Germany 
Laminar flow (for cell 
culture) 
SK1200 BDK Luft- und Reinraumtechnik GmbH, 
Sonnenbühl-Genkingen, Germany 
Microscope (for cell 
culture) 
DM IL Leica Microsystems GmbH, Wetzlar, 
Germany 
MicroScale 
Thermophoresis 
Monolith NT.115 NanoTemper Technologies, Munich, 
Germany 
Microwave Kor-6D07  Daewoo Electronics Europe GmbH, 
Butzbach, Germany 
MilliQ water system MilliQ synthesis Millipore Corporation, Billerica, USA 
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Instrument Name Supplier 
Minicentrifuge Spectrafuge Mini Labnet International Inc., Edison, USA 
Multichannel pipette 
(10µl) 
Discovery Eight-
Channel Pipette 
Labnet International Inc., Edison, USA 
Multichannel pipette 
(100µl) 
Research (multi-
channel) 
Eppendorf AG, Hamburg, Germany 
Multichannel pipette 
(30µl) 
Matrix Equalizer 
Pipette 
Thermo Fisher Scientific, Hudson, USA 
Pipette controller Accu-jet Brand GmbH + Co. KG, Wertheim, 
Germany 
Pipettes (10, 100 and 
1000 µl) 
Research Eppendorf AG, Hamburg, Germany 
Plate reader FLUOstar 
OPTIMA 
BMG LABTECH GmbH, Offenburg, 
Germany 
Plate reader Magellan™ 
Plate Reader  
TECAN US, Durham, NC, USA) 
(available at Institute of Clinical 
Chemistry, University Hospital 
Regensburg, Regensburg, Germany) 
Power supply  
(DNA 
electrophoresis) 
Blue PowerPlus Serva Electrophoresis GmbH, 
Heidelberg, Germany 
Power supply  
(protein 
electrophoresis) 
Blue Power 500 Serva Electrophoresis GmbH, 
Heidelberg, Germany 
Protein 
electrophoresis 
system 
Mini Protean 3 
System 
Bio-Rad Laboratories Inc., Hercules, 
USA 
Semi-dry 
electrophoretic 
transfer cell 
Trans-Blot SD Bio-Rad Laboratories Inc., Hercules, 
USA 
Shaker Rocking Platform VWR International, LLC, West Chester, 
USA 
Shaker (for bacteria) Certomat® R B. Braun Biotech International GmbH, 
Melsungen, Germany 
Spectrophotometer Amersham 
Biosciences 
Ultrospec 2100 
GE Healthcare Bio-Sciences AB, 
Uppsala, Sweden 
Spectrophotometer Nanodrop ND-
1000 
Thermo Fisher Scientific, Hudson, USA 
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Instrument Name Supplier 
Thermocycler T1/T300 
Thermocycler 
Biometra biomedizinische Analytik 
GmbH, Göttingen, Germany 
Thermocycler qRT-
PCR 
ViiA™ 7 System 
Taqman 
Life Technologies, Carlsbad, CA, USA 
Thermomixer Thermomixer 
compact 
Eppendorf AG, Hamburg, Germany 
Transilluminator UST-30_M-8R BioView Ltd., Billerica, MA, USA 
Ultrasonic processor Vibra Cell™ 
VCX400 
Sonics & Materials, Inc., Newtown, USA 
Vortexer Vortexer Genie 2 Scientific Industries, Bohemia, USA 
Water bath Medingen WBT 
12 
P-D Industriegesellschaft mbH 
Prüfgerätewerk Dresden, Dresden, 
Germany 
Water still (for 
buffers) 
2012  GFL Gesellschaft für Labortechnik 
GmbH, Burgwedel, Germany 
 
3.1.11. Software tools 
Table 19: Software tools 
Software Application Supplier 
Ape Plasmid 
Editor 
Sequence Analysis M.Wayne Davis, Department of 
Biology, University of Utah, USA 
ArgusX1 V4.0.81 Agarose gel 
documentation 
biostep GmbH, Jahnsdorf, 
Germany 
BioEdit 
Sequence 
Alignment Editor 
v7.0.9.0 
Sequence alignment Tom Hall, Ibis Therapeutics, 
Carlsbad, USA 
KaleidaGraph 4.1 MicroScale 
Thermophoresis 
NanoTemper Technologies, 
Munich, Germany 
Magellan™ Plate 
Reader 
NO assay TECAN US, Durham, NC, USA 
(available at the Institute of Clinical 
Chemistry, University Hospital, 
Regensburg, Germany) 
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Software Application Supplier 
Nanodrop ND-
1000 v.3.5.2 
Measurement of 
DNA/RNA 
concentration 
Thermo Fisher Scientific, Hudson, 
USA 
ViiA™ 7 System 
software 
qRT-PCR data analysis Applied Biosystems Inc., Foster City, 
USA 
Total lab TL100 
software 
Densitometry of 
immunoblots 
Nonlinear Dynamics, Durham, NC, 
USA 
3.2. Methods 
3.2.1. Cultivation of mammalian cell lines 
Cells were grown in a humidified incubator at 37°C (atmosphere 95% air, 5% CO2). 
The medium, cultivation volume and growth supply are described in Table 20. 
Table 20: Cultivation of mammalian cells 
Cell line Growth medium Growth 
supply 
Cultivation 
volume 
Hek293-
Ebna 
DMEM High Glucose (4,5 g/l) with L-
Glutamine 
100 mm 
dish 
10 ml 
BV-2 RPMI 1640 without L-Glutamine 75 cm2 
flask 
10 ml 
MLEC-
PAI/Luc 
DMEM High Glucose (4,5 g/l) with L-
Glutamine 
100 mm 
dish 
10 ml 
 
DMEM High Glucose (4.5 g/l) with L-Glutamine was supplemented with 10% FBS, 100 
U/ml penicillin and 0.1 mg/ml streptomycin. RPMI 1640 without L-Glutamine is 
supplemented with 5% FBS, 1% of L-Glutamine, 195 nM β -Mercaptoethanol, 100 
U/ml penicillin and 0.1 mg/ml streptomycin. For Hek293-Ebna cells, 1% G418 was 
also supplemented with the DMEM High Glucose medium.  
Human Embryonic Kidney 293 (Hek293)-Ebna cells and MLEC-PAI/Luc (Mink lung 
epithelial cells stably transfected with an expression construct containing a truncated 
PAI-1 promoter fused to the firefly luciferase reporter gene) cells were split for 
propagation at an estimated confluence of 90%. To this end, the medium was 
aspirated and both the cells were washed once with 5 ml of PBS.  
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For Hek293-Ebna cells, no trypsinization was required for the detachment of cells. 
After washing with 1X PBS, corresponding media was pipetted gently onto the cells. 
Cells with media were collected in sterile 15 ml Falcon tubes. The cells were pelleted 
by centrifuging at a speed of 1000 rpm in centrifuge for Falcon tubes in cell culture 
(5810 Eppendorf Centrifuge) at RT. After equally redistributing the cells in the total 
amount of solution, they were split 1:6 to a final volume of 10 ml on a new cell culture 
dish.  
On the other hand, 2 ml of trypsin-EDTA solution was pipetted directly onto the 
MLEC-PAI/Luc cells. The dishes of MLEC-PAI/Luc cells were then incubated for 3-5 
min at 37°C, allowing the cells to detach from the plastic surface. As soon as most 
cells were floating, the trypsinization process was stopped by adding 10 ml of the 
corresponding medium. Cells with media were collected in sterile 15 ml Falcon tubes. 
The cells were pelleted by centrifuging at a speed of 1000 rpm in centrifuge for 
Falcon tubes (in cell culture) at RT. After equally redistributing the cells in the total 
amount of solution, they were split 1:6 to a final volume of 10 ml on a new cell culture 
dish.  
BV-2 microglial cells were split according to a different procedure: first the medium 
was aspirated and replaced with 10 ml of fresh medium. Cells were then scraped and 
3 ml of the suspension were transferred to a fresh flask containing 10 ml of medium. 
 
3.2.2. Cultivation of E.coli 
E.coli cells were cultivated either on LBAmp dishes or in liquid LBAmp medium (for the 
medium’s composition, see Table 8). Plates were incubated ON at 37°C; liquid 
cultures were shaken ON at 37°C to ensure oxygen circulation.  
 
3.2.3. Cloning strategy 
3.2.3.1. Amplification of DNA fragments 
Three variants of the HTRA1 gene [the most frequent HTRA1 haplotype 
(HTRA1:CG), as well as two less common HTRA1 haplotypes (HTRA1:TT and 
HTRA1:CC)] were tagged with a six-amino acid-long Tetracysteine (TC) tag at the C-
terminal end and were cloned into the pCEP4 vector (Invitrogen, Carlsbad, CA, USA). 
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The expression constructs for HTRA1:CG, HTRA1:CC and HTRA1:TT variants 
tagged with TC-tag were constructed by the following procedure. 
 
To obtain the TC-tagged HTRA1:CG and HTRA1:TT expression constructs, two 
steps of amplification were performed. In the first step, coding sequence of 
HTRA1:CG and HTRA1:TT without the stop codon were amplified from expression 
construct for untagged HTRA1:CG variant (an already existing construct available at 
the Institute of Human Genetics, University Hospital Regensburg, Regensburg, 
Germany) and from cDNA of ARPE-19 (human retinal pigment epithelium) cells 
respectively. It is to be noted that ARPE-19 cells are heterozygous for the 
synonymous polymorphisms rs1049331 and rs2293870 (TT/CG). Thus amplified 
coding sequences were subcloned into the pGEM®-T vector for sequencing (see the 
procedure below). In the second step, after sequencing, the correct cDNAs were 
amplified with two reverse complimentary oligonucleotides to introduce a six-amino 
acid-long (Cysteine-Cysteine-Proline-Glycine-Cysteine-Cysteine), peptide sequence 
at the C-terminal end, the “TC-tag. Thus obtained TC-tagged coding sequence of 
HTRA1:CG and HTRA1:TT in pGEM®-T was then restriction digested and ligated into 
the pCEP4 vector (see the procedure below). 
The PCR reaction mixture for amplification of HTRA1:CG and HTRA1:TT fragments 
was prepared according to the following protocol: 
AccuPrime™ PCR Buffer B (5X) 2.5 μl 
5'-Primer (5 µM) 1 μl 
3'-Primer (5 µM) 1 μl 
AccuPrime™ Taq Polymerase 0.25 μl 
Template (cDNA/plasmid) 100-200 ng 
H2O upto 25 μl 
 
PCRs were performed with the following cycling conditions: 
Initial denaturation 95°C 5 min  
Denaturation 95°C 30 s  
Annealing 59°C 30 s 30x  
Extension 72°C 45 s  
Final extension 72°C 5 min  
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The expression construct for TC-tagged HTRA1:CC was obtained by first introducing 
site-directed mutagenesis in pGEM®-T construct for HTRA1:CG variant (available at 
the Institute of Human Genetics, University Hospital Regensburg, Regensburg, 
Germany). The correct sequences were detected by sequencing. Then the amplified 
product was digested by DpnI to get rid of methylated parent plasmid. The amplified 
product was then restriction digested from pGEM®-T vector and ligated into the 
pCEP4 vector (see the procedure below). The PCR reaction mixture for amplification 
of HTRA1:CC fragments was prepared according to the following protocol: 
  
Pfu Ultra HF buffer(10X) 5 μl 
dNTPs (2.5 mM each) 2 μl 
5'-Primer (5 µM) 2 μl 
3'-Primer (5 µM) 2 μl 
DMSO  2 μl 
PfuUltra HF DNA polymerase 1 μl 
Template (plasmid DNA) 100-200 ng 
H2O upto 25 μl 
 
PCRs were performed with the following cycling conditions: 
Initial denaturation 95°C 5 min  
Denaturation 95°C 30 s  
Annealing 55°C 30 s 18x  
Extension 72°C 45 s  
Final extension 72°C 5 min  
 
Primers used for cloning the expression constructs for HTRA1 variants for protein 
expression in cell cultures are listed in Table 14. 
 
3.2.3.2. Agarose gel electrophoresis 
The PCR products were resolved by agarose gel electrophoresis. 1-1.5% agarose 
was dissolved in TBE buffer by heating the solution in the microwave. After cooling 
MATERIALS AND METHODS 
 
41 | P a g e   
the liquid on ice it was mixed with two drops of ethidium bromide solution (AppliChem 
GmbH, Darmstadt, Germany) and poured in a casting tray. The GeneRuler™ DNA 
Ladder Mix (Fermentas International Inc., Burlington, Canada) served as a marker. 
Samples were mixed before loading the gel with a drop of 5X DNA-loading buffer. 
Electrophoresis was performed at 100-200 V in a chamber filled with TBE buffer. 
Amplification products were visualized using the dark hood DH-40 (biostep GmbH, 
Jahnsdorf, Germany). Gel runs were documented with the software ArgusX1 V4.0.81 
(biostep GmbH, Jahnsdorf, Germany) and bands with the correct size were excised 
from the gel. 
 
3.2.3.3. DNA extraction from agarose gels  
DNA extraction from agarose gels was performed with the NucleoSpin® Extract II Kit 
(MACHEREY-NAGEL GmbH & Co. KG, Düren, Germany) according to the 
manufacturer’s instructions. DNA was eluted in 20 μl of H2O.  
 
3.2.3.4. Determination of DNA concentrations 
DNA concentrations were determined in 2 μl of samples with the Nanodrop ND-1000 
spectrophotometer using the Nanodrop ND-1000 v.3.5.2 software (Thermo Fisher 
Scientific, Hudson, USA).  
3.2.3.5. DpnI digestion 
DpnI (New England BioLabs® Inc., Ipswich, USA) digestion of the amplified product of 
HTRA1:CC variant (Section 3.2.3.1) was done. DpnI cut only the methylated 
(adenine) recognition sequence 5’-GATC-3’ from the purified plasmid of “pGEM®-
T+HTRA1:CC”. Thus to get rid of the parent plasmid and proceed the further work 
with only the unmethylated amplified product, DpnI digestion was carried out. For 
digestion, the following components were mixed together in a cup and incubated for 
2 h at 37°C. 
Gel excised PCR product (50 ng/μl) 20 μl 
DpnI 3 μl 
NEBuffer CutSmart® 1 μl 
H2O 6 μl 
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3.2.3.6. A-tailing of blunt-ended PCR fragments 
The polymerases used for the amplifications (Section 3.2.3.1) generated blunt-ended 
fragments because of their 3'-5'-exonuclease proofreading activity. However, for 
subcloning PCR products into the pGEM®-T vector, they needed 3'-A-overhangs. The 
purified PCR fragments were modified with the following A-tailing procedure: 7 μl of 
the purified PCR products was mixed with 1 μl of 2 mM dATP, 1 μl of ThermoPol 
Reaction Buffer (10X) and 0.5 μl of Taq DNA Polymerase (New England BioLabs® 
Inc., Ipswich, USA) in a total reaction volume of 10 μl. The mixture was incubated at 
72°C for 30 min. 
 
3.2.3.7. Ligation into pGEM®-T vector 
Next, subcloning of the PCR products with the pGEM®-T Vector System (Promega 
Corporation, Madison, USA) occurred. Vector and A-tailed PCR products were added 
in a molar ratio between 1:1 and 1:3 to the following ligation reaction. 
2X Rapid Ligation Buffer 5 μl 
T4 DNA Ligase 1 μl 
pGEM®-T Vector 0.5 μl 
Insert 1-3 μl 
H2O upto 10 μl 
 
The ligation was performed either for 1 h at RT or ON at 4°C. 
 
3.2.3.8. Heat shock transformation of competent E.coli cells 
For transformation of competent E.coli DH5α and JM110 cells, the heat shock 
method was applied. 50 μl of DH5α cell suspension was thawed on ice and mixed 
with 5 μl of the ligation reaction. After 30 min incubation on ice, the cells were heat 
shocked for 1 min at 42°C. 5 min incubation on ice followed, before 800 μl of LB 
medium (without antibiotics) was added to the suspension. During the recovery 
phase, cells were incubated for 45 min at 37°C on a shaker. The bacteria were then 
centrifuged at 4500 rpm in tabletop centrifuge for microfuge tubes (Heraeus Biofuge 
Fresco centrifuge) for 3 min at RT and resuspended in 100 μl of LB medium. Finally, 
cells were plated on LBAmp plates and incubated ON at 37°C. 
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For transformation with pGEM®-T vector, 40 μl of X-Gal (40 mg/ml dissolved in 
DMSO) and 20 μl of 0.1M IPTG were additionally plated on LBAmp plates before 
applying the E.coli cells.  
 
3.2.3.9. Selection of positive clones 
A helpful feature of the pGEM®-T vector is the ability to perform a so-called 
“blue/white screening” of recombinant cells on LBAmp plates supplemented with X-Gal 
and IPTG. The uptake site of the insert lies within the coding region of the α-peptide 
of β-galactosidase, an enzyme that catalyzes the hydrolysis of β-galactosides into 
monosaccharides. The organic compound X-Gal is also cleaved by β-galactosidase, 
leading to the accumulation of an insoluble blue product. Bacteria harboring the 
pGEM®-T vector without an insert express β-galactosidase after IPTG induction. The 
colonies will appear blue. However, if an insert is ligated into the vector, the 
transformed cells do not express a functional β-galactosidase protein. They are 
unable to cleave X-Gal and the colonies will remain white. It should be mentioned 
that the E.coli strain DH5α used for transformation does not express a functional 
copy of this gene. Sixteen white clones were picked and inoculated ON into 5 ml 
LBAmp medium for subsequent plasmid preparation and sequencing. 
 
3.2.3.10. Plasmid isolation 
For sequencing and restriction digestion, plasmids were isolated with the 
NucleoSpin® Plasmid Kit (MACHEREY-NAGEL GmbH & Co. KG, Düren, Germany) 
from 4 ml of ON cultures. Isolation was performed according to the manufacturer’s 
instructions. DNA was eluted in 50 μl of H2O and the concentration was determined 
with the Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Hudson, 
USA).  
For transfection of mammalian cell lines, plasmids were isolated with the 
NucleoBond® Xtra Midi Kit (MACHEREY-NAGEL GmbH & Co. KG, Düren, Germany) 
from 100 ml of ON cultures. DNA pellets were reconstituted in 100 μl of H2O and 
diluted to a final concentration of approximately 1 μg/μl.  
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3.2.3.11. Cycle sequencing of inserts 
The correctness of the insert’s sequence was determined by cycle sequencing with 
the BigDye® Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems Inc., Foster 
City, USA). Sequencing reactions were performed with the primers mentioned in 
Table 14. The following components were pipetted on ice: 
BigDye® Terminator Sequencing Buffer (5X)  2 μl 
Primer (10 µM) 1 μl 
BigDye® Terminator v1.1 0.8 μl 
Plasmid DNA 50-100 ng 
H2O upto 10 μl 
 
The cycling conditions were set as follows: 
Initial denaturation 95°C 2 min  
Denaturation 95°C 30 s  
Annealing 58°C 30 s 27 x  
Extension 60°C 3 min  
Final extension 60°C 5 min  
 
The DNA was then precipitated with 2 μl of 3M sodium acetate and 25 μl of 100% 
ethanol at 2800 rpm for 20 min at RT in centrifuge for Falcon tubes (Heraeus 
Megafuge 1.0R centrifuge). After washing with 50 μl of 70% ethanol and subsequent 
centrifugation, the DNA was briefly air-dried, resuspended in 15 μl of Hi-Di™ 
Formamide (Applied Biosystems Inc., Foster City, USA) and transferred to a 96-well 
sample plate. Sequencing was performed with the 3130xl Genetic Analyzer capillary 
sequencer (Applied Biosystems Inc., Foster City, USA). The outputs were aligned to 
the expected sequences with BioEdit Sequence Alignment Editor v7.0.9.0 (Tom Hall, 
Ibis Therapeutics, Carlsbad, USA). 
 
3.2.3.12. Restriction digestion of correct inserts and ligation into target vectors 
Restriction sites compatible with the multiple cloning sites of the pCEP4 vectors 
containing “TC-tagged HTRA1:CG” and “TC-tagged HTRA1:TT” were already 
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introduced in the primers used for amplifying the fragments, which were first 
subcloned into the pGEM®-T vector. The enzymes NotI and XhoI were used for the 
restriction digestion of the TC-tagged HTRA1 variants cloned for protein expression 
in cell culture. To obtain pCEP4 containing TC-tagged HTRA1:CC variant from its 
subclone of pGEM®-T vector, FseI enzyme was used to digest. It is to be noted that, 
for restriction digestion by FseI (a dcm methylation sensitive enzyme), pGEM®-T 
vector containing TC-tagged HTRA1:CC variant were transformed into dam-/dcm- 
competent E.coli JM110 cells. After ligation and obtaining pCEP4 vector containing 
TC-tagged HTRA1:CC variant, the plasmids were transformed into DH5α cells. To 
obtain expression constructs for Strep-tagged HTRA1:CC variant, pCEP4 construct 
for TC-tagged HTRA1:CC (construct obtained as described in Section 3.2.3.1) was 
digested by FseI. The digested fragment was inserted into pEXPR-IBA103 
(consisting of Twin Strep tag) construct for HTRA1:CG variant (already available in 
Institute of Human Genetics, University Hospital Regensburg, Regensburg, 
Germany). The pEXPR-IBA103 construct for HTRA1:CC variant was transformed into 
DH5α cells. 
pGEM®-T plasmids (2-3 μg) carrying a correct insert and the target vectors (2-3 μg) 
were digested at least for 1 h at 37°C. 1 μl of each restriction enzyme from New 
England BioLabs® Inc. (Ipswich, USA) was used. The NEBuffer CutSmart® was 
chosen according to the supplier’s recommendations. After restriction digestion 
fragments were resolved on agarose gels and the fragment of interest was excised 
from the gel. DNA purification was performed according to Section 3.2.3.3. 
Next, ligation into the target vectors was performed. Similar to ligations into pGEM®-
T, vector and insert were added in a molar ratio between 1:1 and 1:3 in the following 
ligation assay: 
 
T4 DNA Ligase Reaction Buffer (10X) 5 μl 
T4 DNA Ligase 1 μl 
Vector 50-100 ng 
Insert (molar ratio vector:insert) 1:1 to 1:3 
H2O ad 10 μl 
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The ligation was performed either for 1 h at RT or ON at 16°C. 
Transformation, selection of positive clones, plasmid isolation and cycle sequencing 
were accomplished as described in the previous sections. 
 
3.2.3.13. Long-term storage of positive clones 
Positive clones were maintained as glycerol stocks for long-term storage. To this end, 
bacteria from 4 ml of fresh overnight culture were pelleted at 4000 rpm in centrifuge 
for Falcon tubes for 3 min at RT. Cells were then resuspended in 500 μl of LB medium 
(without antibiotics) and mixed with 600 μl of sterile 80% glycerol. The stocks were 
immediately frozen at 80°C. 
 
3.2.4. Transfection of Hek293-Ebna cell lines 
For introducing TC-tagged and Strep-tagged HTRA1 expression constructs in 
Hek293-Ebna cells, transfection was performed with the TransIT®-LT1 Transfection 
Reagent (Mirus Bio LLC, Madison, USA), a broad spectrum protein/polyamine-based 
reagent that contains histones and lipids. According to manufacturer’s indications, 
optimal transfection efficiency is reached at a cell confluence of approximately 50-
70%. Transfection of cells grown in a 100 mm dish was performed after 24 h as 
follows: 10 µg of plasmid DNA was diluted and vortexed in 1 ml of the respective 
growth medium without supplements (Table 20). Subsequently 30 µl of TransIT®-LT1 
transfection reagent was added to the tube, which was gently vortexed again. During 
the incubation time of 15-20 min at RT, transfection reagent-DNA complexes were 
formed. The mixture was finally added dropwise to the cells and the culture plate was 
gently shaken and incubated under standard conditions for 48 h. 
 
3.2.5. Secretion assay 
To analyze HTRA1 secretion from Hek293-Ebna cells, cells were seeded ON into 6-
well plates using 3 ml of Opti-MEM® I Reduced Serum Media (Gibco Life 
Technologies). At 70% confluence, the cells were transfected with 2.5 µg of the 
expression constructs for untagged HTRA1 (HTRA1:CG, HTRA1:TT or empty vector) 
and 7.5 µl TransIT-LT1 transfection reagent (Mirus Bio LLC) following the 
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manufacturer’s instructions. Supernatants and cells were harvested 0, 10, 16, 20 and 
24 h after transfection (see Section 3.2.6). Proteins isolated were subjected to 
Western blot analyses against α-HTRA1 and α-ACTB antibodies as described in 
Section 3.2.9. 
 
3.2.6. Preparation of protein samples for gel loading 
Supernatants were collected in 15 ml Falcon tubes (Sarstedt AG, Nürnbrecht, 
Germany) from the top of cells. Supernatants were centrifuged at 1000 rpm in 
centrifuge for Falcon tubes for 3 min at RT to get rid of the debris. Clear supernatants 
were collected and the total protein concentration was measured by Bradford assay 
(see Section 3.2.7). Cells from 100 mm dishes were washed twice with 1X PBS and 
were then resuspended in 1X PBS. The cells in PBS were then transferred into a 15 
ml Falcon tube and centrifuged for 10 min at 4000 rpm in the centrifuge for Falcon 
tubes. The cell pellet was resuspended in 1 ml 1X PBS, transferred into a 1.5 ml 
Eppendorf cup and centrifuged for at 4000 rpm in tabletop centrifuge (for microfuge 
tubes) for 10 min at RT and resuspended in 750 μl of 1X PBS. Total protein 
concentration of the cells was then measured. 
 
3.2.7. Bradford assay for measurement of protein concentration 
To find out the total protein concentration of cells or supernatants, according to 
Bradford assay principle, Roti® Quant solution was used. 10-50 µl of resuspended 
cells or supernatant was added to a mixture of 200 µl of Roti® Quant solution and 800 
µl H2O (Millipore). To calibrate the photometer, a sample was prepared from 800 µl 
H2O and 200 µl Roti® Quant (without protein), which is termed as “Blank”. The 
samples were incubated for 20 min at RT and then the optical density (OD) was 
measured at 595 nm in a photometer. The determination of each protein 
concentration was always done in triplets. The total protein concentration of cells or 
supernatants was then analyzed by comparing with the OD of the titration series of 
known concentration of a protein such as bovine serum albumin (BSA). The total 
protein concentration of each protein in each experiment was equalized before 
subjecting to SDS-PAGE.  
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3.2.8. SDS PAGE (Sodium Dodecyl Sulfate-Polyacrylamide Gel 
Electrophoresis) 
12.5 µl of 5X Laemmli buffer was added to 50 µl of each protein sample and heated 
for 10 min at 95°C before loading onto SDS PAGE.  
 
15% SDS-polyacrylamide gels were poured into the Mini Protean 3 setup (Bio-Rad 
Laboratories Inc., Hercules, USA) using the following mixtures: 
 
Resolving 
gel 
(15%)  
3.75 ml Rotiphorese Gel 40 (29:1) acrylamide/bisacrylamide 
3.38 ml 1 M Tris-HCl pH 8.8  
2.42 ml H2O 
 100 µl 20% SDS  
 100 µl 10% APS  
 10 µl TEMED 
Stacking 
gel 
(3%)  
0.55 ml Rotiphorese Gel 40 (29:1) acrylamide/bisacrylamide 
2.76 ml 1 M Tris-HCl pH 6.8  
 1.69 ml H2O 
 50 µl 20% SDS 
 50 µl 10% APS 
 5 µl TEMED 
 
The gels were transferred to a chamber containing SDS-running buffer and were 
loaded with 25 µl of sample per lane. 4 µl of the PageRuler™ Prestained Protein 
Ladder (Fermentas International Inc., Burlington, Canada) was used as marker. The 
running program was first set at 50 V for approximately 1 h until the samples entered 
the resolving gel and then at 150 V until the bromophenol blue front (contained in 
Laemmli buffer) reached the lower end of the gel. 
 
3.2.9. Western blot (WB)/Immunoblot (IB) 
For Western blot analyses proteins were blotted after SDS-PAGE in the semi-dry 
procedure onto a PVDF membrane. The membrane was activated for 30 s in 
methanol, and then equilibrated for at least 15 min in 1X Towbin transfer buffer. 
Likewise, two 3 mm Whatman Paper and the SDS gel were equilibrated in 1X Towbin 
transfer buffer. The transfer of the proteins from the gel to the membrane was 
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performed for 40 min at 24 V. After transfer, the membrane was pivoted in block 
solution for 1 h at 4°C, before it was incubated ON in the primary antibody. Before 
incubation in secondary antibody (1 h, 4°C), the membrane was washed three times 
for 10 min in 1X PBS. The secondary antibody (Horseradish Peroxidase conjugated) 
was added and the membranes were incubated for at least 1 h at 4°C. The 
membranes were washed again three times with 1X PBS for 10 min.  
 
The protein-antibody complexes were visualized by chemiluminescence using the 
SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific, 
Hudson, USA) according to the manufacturer’s instructions. The blot was exposed to 
CRONEX™ 5 X-ray film (Agfa-Gevaert N.V., Mortsel, Belgium). The films were finally 
developed with the G153 developer and G354 fixer (Agfa-Gevaert N.V., Mortsel, 
Belgium). All antibodies used are enlisted in Table 10. 
 
3.2.10. MicroScale Thermophoresis (MST) to study conformation of 
HTRA1 isoforms 
3.2.10.1. In-Gel TC-tagged HTRA1 detection 
In-Gel detection of the TC-tagged HTRA1 was carried out to identify the optimal 
concentration of FlAsH EDT2 fluorescence labeling reagent (Invitrogen, Carlsbad, 
CA, USA) needed for the TC-tagged HTRA1 to exhibit fluorescence without 
background.  
Hek293-Ebna cells were transfected as described inSection 3.2.4. After 48 h of 
transfection, the supernatant of Hek293-Ebna cells transfected with empty pCEP4 
vector, expression vectors for TC-tagged HTRA1:CG or HTRA1:TT variants were 
harvested as described in Section 3.2.6 and concentrated with Amicon Ultra 10,000 
Kw 4 ml columns (Merck, Millipore, Billercia, MA). 30 µl of concentrated protein was 
mixed with 10 µl of 4x loading dye (Laemmli buffer) without β-Mercaptoethanol and 1 
µl of 80 mM TCEP. The mixture was heated at 70°C for 10 min. The mixture was 
cooled down to RT. 1 µl of 200 µM FlAsH EDT2 in DMSO was added to the mixture. 
This mixture was incubated for another 10 min at RT. 40 µl of respective protein in 
15% SDS Polyacrylamide Gel was run at 150 V for 1 h 20 min. The fluorescent 
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protein bands were visualized in Fujifilm FLA-5000 image scanner (Fujifilm, 
Dusseldorf, Germany). 
 
3.2.10.2. The temperature-dependent structural assays by MST 
MST analyses were performed by Dr. Thomas Schubert, 2bind GmbH, Regensburg, 
Germany. Total protein concentration of the concentrated supernatant of the cells 
transfected with expression vectors containing TC-tagged HTRA1 CC, CG, or TT 
variants was measured by Bradford assay as described in Section 3.2.7. 4 µl of the 
concentrated supernatants (2 µg/µl) were incubated with 1 µl of 20 µM of FlAsH-
EDT2. Samples were incubated for 10 min and sucked into the standard capillaries. 
The capillaries were plugged with paraffin to avoid evaporation. The temperature-
dependent structural assays were performed as biological triplicates at 15% LED 
(light-emitting diode) power and 50% MST power in a Monolith NT.115 (NanoTemper 
Technologies, Munich, Germany) with varied temperatures (32-52 °C). The recorded 
fluorescence of each protein was normalized to the same baseline fluorescence and 
plotted against the temperature into one graph using KaleidaGraph 4.1. 
 
3.2.11. Purification of Strep-tagged variants of the HTRA1 
For purification of the secreted HTRA1 isoforms, 10 ml supernatants of Hek293-Ebna 
cells transfected with expressions constructs for Strep-tagged HTRA1: CG, CC or TT 
variants were collected in Falcon tubes. To get rid of cellular debris, supernatants 
were centrifuged at a speed of 1000 rpm in centrifuge for Falcon tubes for 3 min at RT. 
The purification of heterologously expressed HTRA1 was carried out with the Twin 
Strep Purification Kit from IBA Life Sciences, Göttingen, Germany. 1 ml Gravity flow 
Strep Tactin Superflow® columns were used. W buffer, pH 8.0 (wash buffer) was 
prepared in accordance with Table 4. The buffer E (elution buffer) and R 
(regeneration buffer) were purchased from IBA Life Sciences. 
 
The purification of the proteins was carried out at 4°C with pre-cooled solutions and 
buffers according to the Short Purification Protocol of IBA Life Sciences. Elution of 
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the proteins was carried out in five steps with 500 µl buffer E. The eluate fractions 
were stored in aliquots of 100 µl at -20°C. 
 
3.2.12. Coomassie staining 
The Coomassie staining of SDS gels was carried out directly following the SDS-
PAGE. SDS-gels were stained in Comassie Stainer for 1 h and then destained in 
Coomassie destainer till the distinct protein bands were visible. The composition of 
the solutions was mentioned in Table 4. 
 
3.2.13. Casein digest to test bio-activity of HTRA1 protein 
Bioactivity of HTRA1 protein from supernatant or purified HTRA1 was tested by in 
vitro β-casein digestions. The casein solution used herein contains a casein mixture 
of α-S1 (22 kDa), α-S2 (25 kDa), β (24 kDa), γ (70 kDa) and κ (19 kDa). HTRA1 is 
capable of digesting β-casein. 20 µg of casein from bovine milk (Merck Chemicals 
GmbH, Schwalbach, Germany) was mixed with 2 µg purified HTRA1 isoforms in 100 
µl of digestion buffer pH 7.5 (see Table 4 for composition). After 0 and 3 h, 50 µl 
aliquots were taken and the reaction was stopped by adding 5X Laemmli buffer and 
boiling the sample for 10 min at 90 °C. Samples were resolved by SDS PAGE and 
stained with Coomassie.  
 
3.2.14. Limited partial proteolysis 
25 µl of 40 ng/µl of Strep-purified HTRA1 in 1X elution buffer along with 50 µl of TRIS 
buffer saline (see Table 4 for composition) was preincubated at 37, 42 and 46°C for 
10 min. 25 µl of 480 µg/ml of TPCK-Trypsin (Sigma-Aldrich, St. Louis, MO, USA) in 
TRIS buffer saline was added to denatured HTRA1 at 37°C for another 5 min. 25 µl 
of 5X Laemmli buffer was added to the reaction mixture and boiled. Subsequently, 
samples were subjected to Western blot analyses with α-HTRA1 antibody. 
 
3.2.15. MST interaction analysis 
MST binding experiments were carried out with 100 nM labeled HTRA1 in 
supernatant with varied concentrations of recombinant TGF-β1 (PeproTech, 
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Hamburg, Germany) and β-casein from bovine milk (Sigma-Aldrich, St. Louis, MO, 
USA) at 80% MST power, 20% LED power in standard capillaries on a Monolith 
NT.115 at 25°C. The recorded fluorescence was normalized to the fraction of the 
protein bound (0 = unbound, 1 = bound) and processed with KaleidaGraph 4.1 
software. The data were fitted with the help of the quadratic fitting formula (Kd 
formula) derived from the law of mass action. Each binding experiment was done with 
biological triplicates. MST interaction analyses were performed by Dr. Thomas 
Schubert. 
 
3.2.16. TGF-β1/β-casein in vitro digestion 
TGF-β1 (PeproTech) was dissolved in 10mM citric acid pH 3.0 to make a stock 
concentration of 100 ng/µl. 10 µl from stock, i.e., 1 µg of TGF-β1 was added to 90 µl 
of digestion buffer pH 7.5 (see Table 4 for composition). 1 µg of TGF-β1 was 
incubated with 300 µl serum-free medium of Hek293-Ebna cells transfected with 
expression constructs for HTRA1:CG, HTRA1:TT or control (empty pCEP4 vector) for 
24 h. After 0, 4, 8, 16 and 24 h, 50 µl aliquots were taken from respective 
supernatants. To 50 µl of aliquots, 12.5 µl of 5X Laemmli buffer was added and 
boiled to stop the reaction. 
 
In vitro digestion of β-casein by HTRA1 was analyzed by Karolina Ploessl, Institute of 
Human Genetics, University Hospital Regensburg, Regensburg, Germany. To 
compare β-casein cleavage catalyzed by HTRA1:CG and HTRA1:TT, 20 µg of β-
casein was incubated with 300 µl serum-free medium of Hek293-Ebna cells 
transfected with expression constructs for HTRA1:CG, HTRA1:TT or control (empty 
pCEP4 vector). After 0.5, 1, 2 and 3 h, 50 µl aliquots were taken and the reaction was 
stopped by adding 5X Laemmli buffer and by boiling the sample for 10 min at 90°C. 
Samples were resolved by SDS PAGE and stained with Coomassie.  
 
3.2.17. MLEC luciferase assay 
MLEC-PAI/Luc cells were seeded into 96-well plates at a density of 1.5 × 104 cells per 
well with 100 µl of appropriate medium with growth supplements (Table 20). Cells 
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were allowed to attach for 3 h at 37°C in 5% CO2 incubator. The cells were treated 
with 2 ng/ml of recombinant TGF-β1 (PeproTech) in combination with 40 ng/ml of 
purified HTRA1 (Strep-tagged HTRA1:CG or HTRA1:TT) or eluate of empty vector. 
After 16 h, cultures were centrifuged at a speed of 2500 rpm centrifuge for Falcon 
tubes for 6 min at RT. After washing with 1 ml of PBS, cells were resuspended in 500 
µl of Reporter Lysis Buffer and incubated for 15 min at RT. Cellular debris was then 
pelleted at a speed of 8000 rpm in tabletop centrifuge (for microfuge tubes) for 3 min 
at RT, and 350 µl of the supernatant was transferred to a fresh tube. 10 µl of cell 
lysate was assayed for luciferase activity with 100 µl of Luciferase Assay Reagent 
(Promega Corporation, Madison, USA), which contains the luciferase’s substrate. 
Luminescence was measured in the FLUOstar OPTIMA plate reader (BMG LABTECH 
GmbH, Offenburg, Germany) for 15 s upon injection of the reagent. 
 
3.2.18. Treatment of BV-2 cells with BV-2-conditioned medium and 
HTRA1 
The procedure for inducing endogenous TGF-β signaling in BV-2 cells was followed 
in concordance with Spittau et al. (2013). For this treatment, two sets of BV-2 cells 
were seeded.  
The first set of BV-2 cells were seeded at a density of 1.5 ×105 in 12-well cell culture 
plates with 1.5 ml of appropriate medium with serum and growth supplements (for 
immunocytochemistry) and at a density of 3 ×105 in 6-well cell culture plates with 3 ml 
of appropriate medium with serum and growth supplements (for Western Blot 
analyses and Pai-1 gene expression). Cells were allowed to attach and reach the 
subconfluence for 6 h at 37°C in 5% CO2 incubator. After 6 h, medium with serum 
and growth supplements was replaced by equal volume of serum-free medium. Cells 
were serum-starved for 24 h. After 24 h microglia-conditioned medium from this set of 
BV-2 cells was collected, cellular debris was removed by centrifuging in centrifuge for 
Falcon tubes in (cell culture) at 1000 rpm for 3 min at RT. 
The second set of BV-2 cells was seeded similarly and was allowed to attach and 
grow to subconfluence for similar time and similar condition as for the first set. 
Instead of 24 h, these cells were kept serum-starved for 2 h. After 2 h, the serum-free 
medium was removed. The harvested microglia-conditioned medium of the first set of 
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BV-2 cells was transferred into the second set of BV-2 cells as shown in Figure 8. 
The treatment was continued with the second set of BV-2 cells in the conditioned 
medium. 
 
Figure 8: Schematic overview of inducing autocrine TGF-β/SMAD signaling in 
BV-2 cells. Adapted and modified from Spittau et al. (2013). 
For, SMAD signaling analysis, 40 ng/ml of Strep-tagged HTRA1:CG and HTRA1:TT 
eluates (3 µl of 40ng/µl HTRA1 eluates and equal volume of Strep-tagged empty 
eluate was added to 3 ml of media in six-well plates and 1.5 µl of 40ng/µl HTRA1 
eluates and equal volume of Strep-tagged empty eluate was added to 1.5 ml of 
media in 12-well plates) was added to the BV-2 cells in the conditioned media for 2 h. 
After 2 h, BV-2 cells in 6-well plates were harvested for protein isolation. 
Subsequently, the proteins were subjected to Western blot analyses (Section 3.2.9) 
with SMAD and pSMAD2 antibodies (Table 10). Immunocytochemistry for pSMAD2 
antibody was performed by Magdalena Schneider, Institute of Human Anatomy and 
Embryology, Faculty of Biology and Preclinical Medicine, University of Regensburg, 
Regensburg, Germany, as described in (Friedrich et al., 2015)  
For relative Pai-1 gene expression, BV-2 cells (in conditioned medium) in 6-well 
plates were harvested after 3 h and 24 h of treatment with Strep-tagged HTRA1 
eluates (same concentration as above). The cells were harvested for RNA isolation 
and cDNA treatment (see below). The relative gene expression analysis via 
Quantitative Real-Time PCR (qRT-PCR) was done by Magdalena Schneider as 
described in (Friedrich et al., 2015).  
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3.2.19. BV-2 cells treatment with lipopolysaccharide (LPS) and HTRA1 
BV-2 cells were seeded at a density of 3 ×105 in 6-well plates with 3 ml of media. BV-
2 cells were serum-starved for 24 h before any treatment. To identify an effect of 
HTRA1 on classical activation of microglia, cells were first seeded and serum-starved 
as described before. BV-2 cells were treated with 50 ng/ml LPS for 24 h, (as 
described in Dirscherl et al., 2010; Karlstetter et al., 2014; Aslanidis et al., 2015) in 
presence of increasing HTRA1 concentrations (30 ng/ml, 60 ng/ml and 90 ng/ml). 
After 24 h, cells were harvested for RNA isolation followed by relative gene 
expression analysis and the supernatant was collected for NO assay. 
 
3.2.20. BV-2 cells treatment with interleukin 4 (IL4), TGF-β1 and HTRA1 
BV-2 cells were seeded at a density of 3 ×105 in 6-well plates in 3 ml of appropriate 
medium. The cells were serum-starved for 24 h before any treatment, as described 
before. BV-2 cells were treated separately or in combination with 1 ng/ml of TGF-β1 
and 10 ng/ml of IL4 for 24 h (as described in Zhou et al., 2012) in presence of 
increasing HTRA1 concentrations (30 ng/ml, 60 ng/ml and 90 ng/ml). Cells were 
harvested after 24 h for RNA isolation and relative gene expression analysis. 
 
3.2.21. Nitrite measurement by nitric oxide (NO) assay 
After 24 h, supernatant of LPS- and HTRA1-treated BV-2 cells were harvested. 
Supernatant was centrifuged at a speed of 8000 rpm in tabletop centrifuge (for 
microfuge tubes) for 5 min to get rid of cellular debris. Nitrite measurement was 
carried out with the clear supernatant as per manufacturer’s instruction (Griess 
Reagent System, Promega Corporation, Madison, USA). The colorimetric assay was 
measured in Magellan™ Plate Reader (TECAN US, Durham, NC, USA) (available at 
Institute of Clinical Chemistry, University Hospital Regensburg, Regensburg, 
Germany) according to manufacturer’s instructions. This assay is also known as NO 
assay. 
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3.2.22. RNA analysis  
3.2.22.1. RNA isolation from cell cultures 
Total RNA was isolated from cell cultures with the RNeasy® Mini Kit (Qiagen N.V., 
Hilden, Germany). Before isolating RNA from BV-2 cell lines, they were washed twice 
in PBS. Cells were harvested with a sterile scraper in 600 μl of RLT buffer with 1% β-
mercaptoethanol, freshly added before use. Complete cell wall disruption and 
homogenization was achieved by passing the suspension 20 times through a blunt 
20-gauge needle fitted to a 1 ml syringe. Subsequently, 600 μl of RNase-free 70% 
ethanol was added to the lysate. Further steps were performed according to the 
manufacturer’s protocol including the on-column DNase digestion with the RNase-
Free DNase Set (Qiagen N.V., Hilden, Germany). RNA concentrations were 
determined in 2 μl of samples with the Nanodrop ND-1000 spectrophotometer using 
the Nanodrop ND-1000 v.3.5.2 software (Thermo Fisher Scientific, Hudson, USA). 
After RNA elution in 50 μl of H2O, samples were permanently kept on ice and fast 
processed or stored at -80 °C.  
 
3.2.22.2. First strand cDNA synthesis from RNA 
For first strand cDNA synthesis from RNA the RevertAid™ M-MuLV Reverse 
Transcriptase enzyme (Fermentas International Inc., Burlington, Canada) was used. 
cDNA synthesis was performed with 500-1000 ng of RNA template and random 
primers. As a first step, pre-incubation of RNA for 5 min at 65°C with 1 μl of primers 
(100 pmol) was carried out in 12.5 µl reaction volume, adjusted with RNase-free H2O. 
Afterwards the following components were added on ice: 
RevertAid™ 5X Reaction Buffer (5X) 4 μl 
dNTPs(10 mM each) 2 μl 
RevertAid™ M-MuLV Reverse Transcriptase 1 μl 
H2O(Millipore) 0.5 µl 
 
The reaction mixture was then incubated for 10 min at 25°C, followed incubation at 
42°C for 60 min. The reaction was stopped by heating the mixture to 70°C for 10 
mins. 
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3.2.22.3. qRT-PCR 
qRT-PCR was performed for each sample in triplicates. The cDNA was diluted for the 
qRT-PCR to a concentration of 20 ng/µl. The primer and probe design of all primers 
was carried out via the "Universal Probe Libary" (Hoffmann-La Roche). The PCR 
reactions as shown below were pipetted in a 384-well plate. The PCR was performed 
according to the PCR program shown below using the ViiA™ system 7(Life 
Technologies) machine. The analysis was performed according to the ΔΔCt method. 
Relative gene expressions of classical (M1) microglial activation markers namely 
interleukin 6 (IL6) and inducible nitric oxide synthase (iNOS) or alternative (M2) 
microglial activation markers namely arginase 1 (Arg1) and chitinase 3-like 3 (Ym1) 
were analyzed by normalizing the expression to mouse ATPase, a housekeeper 
gene. All primers and probes used for these experiments are enlisted in Table 16. 
The statistical significance of the test results was determined in Microsoft Excel with a 
Student's t-test. Reaction mixture for qRT-PCR for Arg1, iNOS, IL6, YM1 and mouse 
ATPase are as follows: 
TaqMan Gene Expression Master Mix(MM)(2X) 5 μl 
5'-Primer (50 µM) 1 μl 
3'-Primer (50 µM) 1 μl 
Roche Probe  2 μl 
cDNA 5 µl 
H2O(Millipore) 0.375 µl 
 
Following cycling conditions were set for qRT-PCR: 
 
Denaturation 95°C 40 s 1X 
Annealing 60°C 60 s 1X 
Extension 60°C 2 min 40X 
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4. RESULTS 
4.1. Cloning and expression of HTRA1 variants 
4.1.1. HTRA1 haplotypes applied in subsequent studies 
Three expression constructs for HTRA1 were generated including HTRA1 exon 1 
variants rs1049331:C and rs2293870:G, the reference haplotype (Fritsche et al., 
2008) (referred to as HTRA1:CG), the AMD-associated variants rs1049331:T and 
rs2293870:T (HTRA1:TT), and the non-disease associated variants rs1049331:C and 
rs2293870:C (HTRA1:CC) (Figure 9). 
 
 
Figure 9: Schematic diagram of relative positions of synonymous 
polymorphisms in exon 1 of HTRA1. This scheme is used to illustrate HTRA1 
haplotypes chosen for generating expression constructs for HTRA1 variants; 
HTRA1:CG and HTRA1 CC are not associated with AMD risk, HTRA1:TT is 
associated with increased AMD risk. Figure adapted from Friedrich et al. (2011).  
 
4.1.2. HTRA1 expression constructs 
Expression constructs for untagged HTRA1 variants in pCEP4 vector (already 
available at Institute of Human Genetics, University Hospital Regensburg, Germany) 
were used for analyzing secretion and intracellular accumulation of HTRA1 isoforms 
(Figure 10A). Expression constructs for Strep-tagged HTRA1 variants were used for 
purifying HTRA1. HTRA1:CG and HTRA1:TT variants (in pEXPR-IBA103) were 
already available at Institute of Human Genetics, University Hospital Regensburg, 
Germany. Strep-tagged HTRA1:CC variant was generated within this study (Figure 
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10B). For MST analyses, the three HTRA1 variants were C-terminally fused to a 
Tetracystein (TC)-motif (Cys-Cys-Pro-Gly-Cys-Cys), allowing labeling with FlAsH-
EDT2 to show fluorescence. (Figure 10C). 
 
Figure 10: Schematic representation of expression constructs for (A) untagged, 
(B)TC-tagged and (C)Strep-tagged HTRA1 variants. Vector backbones used for 
heterologous expression of HTRA1 variants are depicted: pCEP4 (Figure modified 
and adapted from www.invitrogen.com) was used for heterologous expression of (A) 
untagged HTRA1, as well as (B) TC-tagged HTRA1 variants. pEXPR-IBA103 (Figure 
modified and adapted from www.iba-lifesciences.com) was used for generating (C) 
Strep-tagged HTRA1 variants. Restriction sites used for inserting HTRA1 variants are 
labeled within the figures. 
 
4.1.3. Characterization of HTRA1 expression constructs 
Before performing experiment with heterologously expressed HTRA1 variants, the 
expressed proteins were subjected to quality control by Bradford Assay, Western Blot 
and casein in vitro digest (Figure 11). Cells transfected with expression constructs for 
HTRA1 variants were harvested. The total protein concentration was measured by 
using Bradford assay and equal amount of respectively tagged or untagged proteins 
were subjected to Western blot to compare the expression of both AMD non-risk- and 
risk-associated HTRA1 isoforms (exemplarily shown for HTRA1:CG and HTRA1:TT 
in Figure 11). 300 µl of the supernatants were incubated with casein for 3 h to test for 
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HTRA1 bioactivity (exemplarily shown for HTRA1:CG and HTRA1:TT in Figure 11), 
as described in (Murwantoko et al., 2004; Vierkotten et al., 2011; Eigenbrot et al., 
2012). 
 
Figure 11: Characterization of HTRA1 expression and bioactivity. Hek293 cells 
were transfected with expression constructs for HTRA1:CG and HTRA1:TT variants. 
These HTRA1 variants were either untagged (A and D) or TC-tagged (B and E) or 
Strep-tagged (C and F). Immunoblots were performed with cell lysates using α-
HTRA1 antibodies. The β-actin (ACTB) immunoblot served as loading control. For 
analyzing bio-activity of untagged and TC-tagged HTRA1 isoforms (D and E) 
respectively, 300 µl of serum-free supernatants were mixed with 20 µg of β-casein 
and incubated at 37°C over a period of 3 h. Samples were taken after 0 h and 3 h 
and subjected to SDS-PAGE with subsequent Coomassie staining. For analyzing bio-
activity of Strep-tagged HTRA1 (F), first 10 ml of serum-free supernatants of Hek293 
cells transfected with expression constructs of Strep-tagged HTRA1 variants were 
used to purify the HTRA1 isoforms in Strep Tactin Superflow® columns according to 
manufacturer’s instructions. After purification 5 µg of each purified Strep-tagged 
HTRA1 isoform was mixed with 20 µg of β-casein and incubated at 37°C over a 
period of 3 h. Samples taken after 0 h and 3 h were subjected to Coomassie staining 
and analyzed as described above. 
 
The bio-activity of HTRA1:CG and HTRA1:TT isoforms did not show any significant 
difference. This result was consistent whether the isoforms were untagged, TC-
tagged or Strep-tagged. 
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4.2 Influence of synonymous SNPs within HTRA1 exon 1 on protein 
structure 
To assess protein folding properties of the different HTRA1 haplotypes, MST, a 
method which determines the movement of molecules along a temperature gradient, 
was applied (Duhr and Braun, 2006; Baaske et al., 2010). The thermophoretic 
movement is sensitive to changes in the molecular structure or conformation, thus 
allowing detection of minimal alterations of protein variants or complexes.  
 
For monitoring purposes, a C-terminal tetracysteine (TC)-tag motif was fused to each 
of the haplotype constructs providing a specific fluorescent labeling of the translated 
protein (Adams et al., 2002; Madani et al., 2009). The TC-tagged haplotype 
constructs were then fused into pCEP4 expression vector (Invitrogen, Carlsbad, 
USA). Therefore, TC-tagged HTRA1 variants were heterologously expressed in 
Hek293 cells. After 72 h, supernatants were harvested, TC-tagged HTRA1 isoforms 
within the supernatants were labeled by a fluorescent dye and MST analyses were 
performed with the labeled HTRA1 isoforms. 
4.2.1. Preparation and adjustment of TC-tagged HTRA1 isoforms  
After harvesting the supernatant from Hek293 cells transfected with expression 
vectors containing the different TC-tagged HTRA1 variants, the supernatants were 
concentrated by Amicon Ultra 10,000 Kw 4 ml columns and the total protein 
concentrations were measured by Bradford assay. The protein concentration of all 
supernatants containing TC-tagged HTRA1 isoforms were adjusted to 2 µg/µl and 
subjected to Western blot.   
Figure 12: Adjustment of HTRA1 concentrations 
in supernatant of Hek293 cells transfected with 
expression vectors containing TC-tagged HTRA1 
variants. (A) Supernatants of transfected Hek293 
cells with expression vectors for TC-tagged variants 
or control (empty expression vector) were adjusted 
to a protein concentration of 2 µg/µl and subjected to 
Western blot analyses using α-HTRA1 antibodies. 
(B) Densitometry analysis of relative HTRA1 protein 
levels from (A), calibrated against measurements for 
HTRA1:CG. Data represent the mean +/- SD of 
three independent immunoblots before each 
independent MST analyses. 
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Each supernatant of Hek293 cells transfected with expression constructs for either 
TC-tagged HTRA1:CG, HTRA1:CC or HTRA1:TT variants showed similar HTRA1 
protein level (Figure 12). 
 
4.2.2. Labeling TC-tagged HTRA1 with FlAsH-EDT2 for MST analyses 
The biarsenical labeling reagent FlAsH-EDT2, used in bioanalytical research, 
becomes fluorescent upon binding to TC-tagged recombinant proteins containing the 
tetracysteine (TC) motif (Adams et al., 2002; Adams and Tsien, 2008). In order to 
label TC-tagged HTRA1, the supernatants were incubated with 5 µM concentration of 
FlAsH-EDT2 according to manufacturer’s instructions. The labeled samples were 
subjected to SDS-PAGE and the image was captured by Fujifilm FLA-5000 image 
scanner (available at the Institute of Microbiology, Faculty of Biology and Preclinical 
Medicine, University of Regensburg, Germany). 
 
Figure 13: Labeling TC-tagged HTRA1 with FlAsH-
EDT2 for MST analyses. The following samples were 
loaded (from left to right): Medium: Serum-free 
medium for Hek293 cells; FlAsH-EDT2: 5 µM FlAsH-
EDT2 labeling reagent; HTRA1:CG: TC-tagged 
HTRA1:CG labeled with 5 µM FlAsH-EDT2 in 
supernatant of Hek293 cells transfected with 
expression construct for TC-tagged HTRA1:CG 
variant; HTRA1:TT: TC-tagged HTRA1:TT labeled with 
5 µM FlAsH-EDT2 in supernatant of Hek293 cells 
transfected with expression construct for TC-tagged 
HTRA1:TT variant; and control: supernatant of Hek293 
cells transfected with empty vector, labeled with 5 µM 
FlAsH-EDT2. 
 
Figure 13 illustrates that 5 µM concentration of FlAsH-EDT2 specifically binds to TC-
tagged HTRA1:TT and CG isoforms but did not give any signal in the control 
(supernatant of cells transfected with empty pCEP4 vector). The free dye also does 
not show any fluorescence. 
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4.2.3. HTRA1:CG, HTRA1:TT and HTRA1:CC protein conformation 
comparison by MST  
Adjusted and labeled HTRA1 variants in supernatants were subjected to MST 
analyses by increasing the temperature gradually from 32°C to 52°C, with an interval 
of 2°C. The thermophoretic mobility of each HTRA1 isoform at the given temperature 
was recorded in Monolith NT.115 (NanoTemper Technologies, Munich, Germany). 
MST analyses were carried out by Dr. Thomas Schubert, 2bind GmbH, 
Regensburg,Germany. 
 
Figure 14: MST analysis of 
HTRA1:CG, HTRA1:TT and 
HTRA1:CC. TC-tagged HTRA1 
isoforms were heterologously 
expressed in Hek293 cells. 
TC-tagged HTRA1 was labeled 
with a FlAsH-EDT2, and 
subjected to MST analyses. 
Electrophoretic mobility of the 
fluorescent protein was 
assessed at increasing 
temperatures (from 32°C to 
52°C). Supernatant of cells 
transfected with an empty 
vector were used for 
normalization. Data represent 
the mean +/- standard deviation 
(SD) of three independent 
experiments. The MST 
analyses were done by Dr. 
Thomas Schubert, 2bind 
GmbH, Regensburg, Germany.  
 
MST analyses revealed a similar thermal migration behavior of the HTRA1 isoforms 
HTRA1:CG and HTRA1:CC. In contrast, HTRA1:TT exhibited a significantly different 
thermophoretic mobility suggesting an influence of AMD-associated polymorphisms 
rs1049331:T and rs2293870:T on the tertiary structure of the protein (Figure 14). 
4.3. HTRA1:CG, HTRA1:TT and HTRA1:CC protein conformation 
comparison by limited partial proteolysis 
In an independent approach, structural differences of the three protein isoforms were 
assessed by partial proteolysis. This assay is sensitive to detect minor alterations in 
protein structure by measuring the susceptibility of the protein substrate for proteases 
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such as Trypsin (Park and Marqusee, 2005; Kimchi-Sarfaty et al., 2007; Kim et al., 
2009; Na and Park, 2009). 
 
Figure 15: Partial proteolysis of 
recombinant HTRA1:CG, HTRA1:TT 
and HTRA1:CC with Trypsin. Strep-
tagged HTRA1 isoforms were purified 
after heterologous expression in 
Hek293 cells. 1 µg of purified HTRA1 
was incubated for 10 min at 37, 42 and 
46 °C, respectively. Proteolysis was 
performed at 37°C for 5 min with 120 
µg/ml Trypsin. Samples were subjected 
to Western blot analysis with α-HTRA1 
antibodies. (A) shows a representative 
immunoblot. (B) shows densitometric 
analysis of immunoblots of three 
independent experiments from (A). 
HTRA1 signals were calibrated with 
measurements for HTRA1:CG after 
preincubation at 37°C. Data represent 
the mean +/- SD. Asterisks mark 
significant (*P < 0.05) and highly 
significant differences (**P < 0.01) 
between relative amounts of protein for 
HTRA1:CG or HTRA1:CC and 
HTRA1:TT. 
 
Figure 15A shows that HTRA1:TT was more susceptible to trypsin digestion than 
HTRA1:CG or HTRA1:CC under partial denaturing conditions. A strong decrease of 
HTRA1:TT was observed after preincubation at 42°C, and after preincubation at 
46°C, HTRA1:TT was completely digested. In contrast, no significant reduction of 
HTRA1:CG and HTRA1:CC, subjected to these conditions, was observed. Figure 
15B shows that the differences in protein levels between HTRA1:CG or HTRA1:CC 
and HTRA1:TT were statistically significant after preincubation at 42°C (P<0.05), and 
highly significant after preincubation at 46°C (P<0.01). Autoproteolysis of HTRA1 was 
negligible. Together, the results from MST analyses and from partial proteolysis 
suggest that HTRA1:CG and HTRA1:CC exhibit a similar tertiary structure that is 
different from HTRA1:TT. With a further focus on the functional relevance of the 
altered structure of HTRA1:TT, its properties were compared with that of the HTRA1 
isoform translated from the reference haplotype, namely HTRA1:CG.  
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4.4. Influence of synonymous SNPs within HTRA1 exon 1 on protein 
secretion 
Secreted proteins are subjected to ER quality control which retains and eventually 
degrades misfolded protein species with a high sensitivity towards minor structural 
alterations (Ruggiano et al., 2014). Secretion of HTRA1:CG and HTRA1:TT in 
Hek293 cells was therefore monitored. Supernatant and cells were collected at 
various time points between 0 h and 24 h after transfection with expression 
constructs for HTRA1:CG and HTRA1:TT (Figure 16). 
 
 
Figure 16: Influence of synonymous polymophisms on secretion of HTRA1 
analyzed by immunoblot. After transfection of Hek293 cells with expression 
constructs for HTRA1:CG, HTRA1:TT or control, cells and cell culture medium 
(supernatant) were harvested at the indicated time points (0 to 24 h) and subjected to 
Western blot analyses with α-HTRA1 antibodies. The ACTB immunoblot served as 
loading control (A). Densitometric quantification of immunoblots of three independent 
repetitions of experiments from focusing on (B) intracellular or (C) extracellular 
HTRA1 protein shows HTRA1 signals were normalized against ACTB and calibrated 
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against measurements for HTRA1:CG at 24 h. Data represent the mean +/- SD. 
Asterisks indicate statistically significant (*P < 0.05) and highly significant differences 
(**P < 0.01) between relative amount of protein for HTRA1:CG and HTRA1:TT. 
 
Western blot analyses were performed with α-HTRA1 antibody. At 0 h, no HTRA1 is 
detected. There is a strong increase in HTRA1 expression from 16 to 24 h. However, 
relative to HTRA1:CG, intracellular amounts of HTRA1:TT were increased with a 
statistically significant difference at 24 h (P < 0.05) (Figure 16A and B). Contrary to 
this, a statistically significant reduction of HTRA1:TT protein relative to HTRA1:CG 
was detected in the supernatant at 20 h and 24 h (Figure 16A and C). At time points 
20 h and 24 h, the differences in amounts of extracellular protein of HTRA1:CG and 
HTRA1:TT were statistically significant (P < 0.05) (Figure 16C). 
Cumulatively, these data suggest a delayed secretion of HTRA1:TT relative to 
HTRA1:CG. 
 
4.5. Influence of synonymous SNPs within HTRA1 exon 1 on its 
substrate affinity 
4.5.1. Interaction of HTRA1 isoforms with TGF-β and β-casein analyzed 
by MST 
Several studies demonstrated a inhibiting influence of HTRA1 on TGF-β signaling, 
although the type of interaction between the two molecules remained debatable (Oka 
et al., 2004; Shiga et al., 2011; Zhang et al., 2012; Graham et al., 2013; Karring et al., 
2013). To investigate the interplay between HTRA1 and TGF-β, thermophoretic 
mobility of TC-tagged HTRA1 dependent on increasing TGF-β1 concentrations was 
measured using MST analyses. In order to label TC-tagged HTRA1 isoforms with 
FlAsH-EDT2 dye, supernatants of Hek293 cells transfected with expression 
constructs for TC-tagged HTRA1:CG and HTRA1 TT were incubated with 5 µM 
FlAsH-EDT2. 100 nM of each labeled HTRA1 isoform was incubated with increasing 
concentration of purified TGF-β1 ranging from 0.122 nM to 4000 nM or with β-casein 
(from 1,22 nM to 40 µM). At a constant temperature of 25°C, at 80% MST power and 
20% LED power, the binding affinity of fluorescently labeled HTRA1:CG and 
HTRA1:TT with TGF-β1 was recorded on a Monolith NT.115. 
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Figure 17: HTRA1 and its interaction with TGF-β1 and β-casein as measured by 
MST. Fluorescence-labeled HTRA1 (100 nM) was incubated with increasing 
concentrations of (A) TGF-β1 (0.122 nM to 4000 nM) or (B) β-casein (1.22 nM to 
40,000 nM). Protein-protein interactions for HTRA1 and TGF-β1 were quantified by 
MST and binding data were plotted applying the Hill equation. The recorded 
fluorescence was normalized to the fraction bound (0 = unbound, 1 = bound). Data 
represent the mean +/- SD of three independent experiments. MST analyses were 
performed by Dr. Thomas Schubert, 2bind GmbH, Regensburg, Germany. 
 
The analyses of the MST interaction of HTRA1 isoforms and TGF-β1 were performed 
by Dr. Thomas Schubert, 2bind GmbH, Regensburg, Germany. For HTRA1:CG in the 
presence of mature TGF-β1, a typical sigmoidal binding curve with a binding affinity 
of 63.2 +/- 8.8 nM was observed (Figure 17A). These results support a direct 
interaction between HTRA1 and mature TGF-β. In comparison, HTRA1:TT isoform 
failed to interact with TGF-β1 (Figure 17A). In contrast, titration of HTRA1 with its 
substrate β-casein revealed a similar sigmoidal binding curve for both HTRA1 
isoforms, HTRA1:CG and HTRA1:TT. The binding affinities were 527.9 +/- 96.4 nM 
for HTRA1:CG, and 410.3 +/- 77.4 nM for HTRA1:TT, with the differences in binding 
affinities not being statistically significant (Figure 17B). 
 
4.5.2. Proteolytic cleavage of TGF-β and β-casein by different HTRA1 
isoforms 
Next, the proteolytic capacity of HTRA1:CG and HTRA1:TT for TGF-β and β-casein, 
was analyzed respectively. Supernatants of Hek293 cells transfected with expression 
vectors for HTRA1:CG, HTRA1:TT and control (empty expression vector) were 
harvested. HTRA1 protein concentration in supernatant containing each HTRA1 
isoform was 15 ng/µl. 4.5 µg of HTRA1 (in 300 µl supernatant) was incubated with 1 
µg of TGF-β1 for 24 h and 20 µg of β-casein for 3 h. Same volume of supernatants 
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transfected with empty expression vector were incubated with TGF-β1 and β-casein 
similarly. This served as control. After 0, 4, 8, 16 and 24 h, samples were collected 
from each mixture of TGF-β1 incubated with HTRA1:CG, HTRA1:TT and control. 
Samples for casein-containing mixtures were collected at 0, 0.5, 1 and 3 h. The 
casein in vitro digestion and the densitometry analysis of three independent 
experiments was performed by Karolina Ploessl, Institute of Human Genetics, 
University Hospital Regensburg, Regensburg, Germany. 
 
Co-incubation of HTRA1:CG with mature TGF-β1 resulted in a gradual digestion of 
TGF-β1. However, TGF-β1 cleavage by HTRA1:TT was strongly reduced compared 
to HTRA1:CG (Figure 18A). Densitometry of three independent experiments 
revealed that approximately 85% of TGF-β1 was cleaved by HTRA1:CG after 4 h, 
whereas only 10% of TGF-β1 cleavage was observed in the presence of HTRA1:TT. 
After 16 h, TGF-β1 was completely cleaved by HTRA1:CG, while at this time point 
almost 60% of mature TGF-β1 was still present when incubated with HTRA1:TT 
(Figure 18B). The observed differences for TGF-β1 cleavage by HTRA1:CG and 
HTRA1:TT were statistically highly significant (P < 0.01). 
 
 
Figure 18: Proteolysis of TGF-β1 and β-casein by HTRA1:CG, HTRA1:TT or 
control. (A) 1 µg of TGF-β1 or (C) 20 µg of casein were mixed with 300 µl serum-
free medium of transfected Hek293 cells, containing 15 ng/µl of each HTRA1 isoform 
and incubated at 37°C. As a control, supernatant of Hek293 cells transfected with the 
empty expression vector was used. Samples were taken at the indicated time points. 
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TGF-β1 proteolysis was captured via Western blot analyses with α-TGF-β antibody; 
casein digest was followed by Coomassie staining. Casein digest was conducted by 
Karolina Ploessl, Institute of Human Genetics, University Hospital Regensburg, 
Regensburg, Germany. Three independent experiments as described in (A) and (B) 
were performed and subjected to densitometric analysis for TGF-β1 (B) or β-casein 
(D). TGF-β1 or β-casein signals were calibrated against measurements for 
HTRA1:CG at 0 h. Data represent the mean +/- SD. Asterisks indicate statistically 
highly significant differences (**P<0.01) between TGF-β1 cleavage by HTRA1:CG 
and HTRA1:TT, respectively. Densitometry analysis for casein digest was performed 
by Karolina Ploessl, Institute of Human Genetics, University Hospital Regensburg, 
Regensburg, Germany.  
 
In contrast to the effect of synonymous polymorphisms on TGF-β1 cleavage, both 
HTRA1 isoforms exhibited similar proteolytic activities for the β-casein substrate 
(Figure 18C and D). 
 
4.6. Effect of HTRA1:CG and HTRA1:TT on TGF-β signaling 
The different affinities of HTRA1:CG and HTRA1:TT for TGF-β indicate that the two 
variants might also exhibit different effects on TGF-β-induced signal pathways. 
Therefore, the effect of HTRA1:CG and HTRA1:TT on TGF-β signaling was 
investigated. 
4.6.1. Effect of HTRA1:CG and HTRA1:TT on TGF-β1-induced PAI-1 
promoter activity in MLEC-PAI/Luc cells. 
A reporter assay based on MLEC-PAI/Luc cells was used to analyze the effect of 
HTRA1 on TGF-β1 signaling. These cells are stably transfected with a luciferase-
coding sequence under the control of the TGF-β-responsive element of the PAI-1 
promoter, and thus, respond to stimulation by TGF-β family members (e.g. TGF-β1) 
with heterologous luciferase expression (Abe et al., 1994). MLEC-PAI/Luc cells were 
treated with 2 ng/ml of TGF-β1 in presence of Strep-tagged HTRA1:CG and 
HTRA1:TT, or control protein (purified from supernatant of empty Strep-vector 
transfected cells) for 16 h. 
Addition of HTRA1:CG to MLEC-PAI/Luc cells resulted in a strong reduction of TGF-
β1-activated luciferase expression (15.6 +/- 2.8% luciferase activity compared to 
control cells). HTRA1:TT was also capable of inhibiting TGF-β1-activated luciferase 
expression, but only at 64.6 +/- 21.1% (Figure 19). The difference in luciferase 
expression between cells treated with HTRA1:CG and HTRA1:TT was statistically 
highly significant (P < 0.01). 
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Figure 19: Effect of HTRA1:CG and HTRA1:TT on TGF-
β1-induced PAI-1 promoter activity in MLEC-PAI/Luc 
cells. MLEC-PAI/Luc cells were stimulated with 2 ng/ml 
TGF-β1 in the presence of 40 ng/ml HTRA1:CG, or 
HTRA1:TT purified from supernatants of Hek293 cells 
transfected with expression constructs for Strep-tagged 
HTRA1 variants, or control protein (purified from 
supernatant of empty Strep-vector-transfected cells). After 
16 h, luciferase activity was measured in triplicate wells 
each in three independent experiments. Measurements for 
each experiment were calibrated against the control (TGF-
β1 + control protein). The mean +/- SD for the three 
independent experiments is given for each treatment. 
Asterisks indicate statistically highly significant differences 
(**P < 0.01). 
 
 
4.6.2. Effect of HTRA1:CG and HTRA1:TT on SMAD phosphorylation  
TGF-β signaling has been reported to be an important regulator of microglial 
development and activation (Suzumura et al., 1993; Paglinawan et al., 2003; Li et al., 
2008; Butovsky et al., 2014). Specifically, extracellular binding of TGF-β family 
members by TGF-β receptors lead to phosphorylation of SMAD proteins (Javelaud 
and Mauviel, 2004a, b, 2005), important mediators of TGF-β-induced signaling 
cascades. Therefore, the influence of HTRA1:CG and HTRA1:TT on the 
phosphorylation of SMAD2 in BV-2 micoglial cells was analyzed. Autocrine SMAD 
phosphorylation was triggered in BV-2 cells by adding BV-2-conditioned medium to 
serum-starved BV-2 cells as described in Spittau et. al (2013). BV-2 cells (in 
conditioned medium) were treated for 2 h with 40 ng/ml of Strep-tagged HTRA1:CG, 
HTRA1:TT or control protein. The control protein was purified from supernatant of 
cells transfected with empty Strep-vector (pEXPR-IBA103). Immunocytochemistry of 
the treated cells with antibody against pSMAD2 was carried out by Magdalena 
Schneider, Institute of Human Anatomy and Embryology, Faculty of Biology and 
Preclinical Medicine, University of Regensburg, Germany (Figure 20A).  
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Figure 20: Effect of HTRA1 variants on SMAD-phosphorylation analyzed via 
immunocytochemistry. BV-2 cells (in conditioned medium) were treated for 2 h with 
protein purified from supernatant of cells transfected with empty Strep-vector (control) 
(Left); HTRA1:CG (Centre) and HTRA1:TT (Right). Subsequently, the cells were 
subjected to immunocytochemistry with antibodies against pSMAD2 (performed by 
Ms. Magdalena Schneider, Institute of Human Anatomy and Embryology, Faculty of 
Biology and Preclinical Medicine, University of Regensburg, Germany) (A) or to 
immunoblot analyses using antibodies against pSMAD2, SMAD2 and ACTB (B). (C) 
Densitometry quantification of immunoblots was analyzed from (B) with three 
independent experiments. Signals for pSMAD2 and SMAD2 were normalized against 
ACTB and calibrated against the control. Data represent the mean +/- SD. Asterisks 
indicate statistically highly significant differences (**P < 0.01). 
 
Immunocytochemistry with control cells showed a strong immunoreactivity for 
phosphorylated SMAD2 (pSMAD2) within BV-2 cells, indicating an activated TGF-β 
signaling pathway by endogenously synthesized and secreted TGF-β proteins 
derived from BV-2-conditioned medium (Figure 20A Left). This result is in full 
agreement with data on autocrine TGF-β expression and signaling in microglial cells 
(Spittau et al., 2013). BV-2 cells treated with HTRA1:CG exhibited a significantly 
reduced signal intensity of pSMAD2 indicating an inhibiting effect of HTRA1:CG upon 
TGF-β signaling (Figure 20A Centre). In contrast, staining for pSMAD2 in BV-2 cells 
treated with HTRA1:TT had a similar intensity as in the control experiment (Figure 
20A Right).  
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To quantify the effects of HTRA1 isoforms on SMAD phosphorylation, Western blot 
analyses were performed with protein isolated from BV-2 cells treated as described 
above.  
 
The data of immunoblot analyses show that SMAD2 phosphorylation is almost 
completely absent in BV-2 cells treated with HTRA1:CG, while HTRA1:TT reduced 
measurable pSMAD2 levels to 71.9 +/- 2.5% compared to control (20B and C). While 
the amounts in SMAD2 protein were comparable, the observed differences in 
phosphorylated pSMAD2 were statistically highly significant (P < 0.01) (Figure 20C).  
 
4.6.3. Effect of HTRA1:CG and HTRA1:TT on relative Pai-1 gene 
expression  
PAI-1 is a prominent target gene of TGF-β signaling (Cao et al., 1995; Kutz et al., 
2001; Dong et al., 2002). Upon TGF-β stimulation, phosphorylated SMAD2 and 
SMAD3 form a complex with SMAD4, which is then translocated into the nucleus. 
This complex stimulates expression of TGF-β response genes (Javelaud and 
Mauviel, 2004b, a, 2005). Autocrine TGF-β signaling was triggered in BV-2 cells by 
adding BV-2-conditioned medium to serum-starved BV-2 cells as described in Spittau 
et. al (2013). BV-2 cells in conditioned medium were treated with 40 ng/ml Strep-
tagged HTRA1:CG and HTRA1:TT for 3 h and 24 h.  
 
Figure 21: Effect of HTRA1:CG and 
HTRA1:TT on relative Pai-1 gene 
expression in BV-2 cells. BV-2 cells were 
treated for 3 and 24 h with recombinant 
HTRA1:CG, HTRA1:TT or control protein. PAI-
1 mRNA expression was determined via qRT-
PCR by Ms. Magdalena Schneider and Dr. 
Rudolf Fuchshofer, Institute of Human 
Anatomy and Embryology, Faculty of Biology 
and Preclinical Medicine, University of 
Regensburg, Germany. Experiments were 
performed in triplicates in four independent 
experiments. Results were normalized to the 
transcript levels of a mouse housekeeper 
gene, GNB2L and calibrated with the control at 
3 h and 24 h, respectively. The mean +/- SD 
for the four independent experiments are 
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given. Asterisks indicate statistically significant (*P < 0.05) and highly significant 
differences (**P < 0.01).  
 
After 3h and 24 h respectively, RNA was isolated from the treated cells and cDNA 
was synthesized. The relative Pai-1 gene expression was analyzed via qRT PCR by 
Magdalena Schneider and Dr. Rudolf Fuchshofer, Institute of Human Anatomy and 
Embryology, Faculty of Biology and Preclinical Medicine, University of Regensburg, 
Germany (Figure 21). A strong downregulation of Pai-1 mRNA expression was noted 
in BV-2 cells treated with HTRA1:CG when compared to control cells (12.5 +/- 12.9% 
after 3 h; 14.5 +/- 13.9% after 24 h). In contrast, a less prominent decrease of Pai-1 
transcripts was found after treatment with HTRA1:TT (74.0 +/- 35.5% after 3 h; 56.8 
+/- 29.6% after 24 h, compared to control cells). The difference in Pai-1 expression 
following treatment with HTRA1:CG or HTRA1:TT was statistically significant (P < 
0.05) (Figure 21).  
 
4.7. Effect of HTRA1 on microglial activation  
Microglial activation and differentiation is strongly regulated by TGF-β signaling 
(Rozovsky et al., 1998; Huang et al., 2010; Cekanaviciute et al., 2014; Norden et al., 
2014). As HTRA1 has been found to play a role in TGF-β signaling in microglial cells, 
the effect of HTRA1 on microglial activation was investigated. 
4.7.1. Effect of HTRA1 on classical activation of microglial (BV-2) cells via 
LPS treatment 
To activate classical (M1) microglial activation, 50 ng/ml of LPS was used in various 
studies (Dirscherl et al., 2010; Karlstetter et al., 2014; Aslanidis et al., 2015). The 
effect of HTRA1 on LPS-activated microglia was observed by treating the BV-2 cells 
with 50 ng/ml of LPS in presence of increasing HTRA1 concentrations. A key 
microglial enzyme induced in this process is the inducible nitric oxide synthase 
(iNOS), which utilizes arginine to produce nitric oxide (Bagasra et al., 1995). Nitrite 
production was thus measured as a marker for M1 activation. BV-2 cells, serum-
starved for 24 h, were treated with increasing concentrations of Strep-tagged HTRA1 
(30, 60 and 90 ng/ml) in presence or absence of 50 ng/ml LPS. 
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Figure 22: Effect of HTRA1 on nitrite production in BV-2 cells. BV-2 cells were 
serum-starved for 24 h before treatment. After 24 h, increasing concentration (30, 60, 
90 ng/ml) of Strep-tagged HTRA1 was added to BV-2 cells in presence 0 or 50 ng/ml 
of LPS. After 24 h of treatment, nitrite production (in µM) was measured from the 
supernatant via NO assay. The mean +/- SD for the three independent experiments 
is given.  
 
After 24 h, the NO assay revealed significant difference in nitrite production in non-
activated (1.2 +/- 0.2 µM) and LPS-activated BV-2 cells (20.7 +/- 0.4 µM). However, 
there was no effect of HTRA1 on nitrite production by BV-2 cells in this in vitro assay 
(Figure 22). 
In the next step, the relative mRNA expressions of M1 markers, iNOS and IL6, were 
analyzed by qRT-PCR. BV-2 cells were treated with LPS and HTRA1 as described 
above. After 24 h RNA was isolated and gene expression of iNOS and IL6 was 
analyzed via qRT-PCR.  
 
Figure 23: Effect of HTRA1 on relative mRNA expression of M1 markers of BV-2 
cells induced by LPS. BV-2 cells were serum-starved for 24 h before treatment. BV-
2 cells were serum-starved for 24 h before treatment. After 24 h, increasing 
concentrations (30, 60 and 90 ng/ml) of Strep-tagged HTRA1 was added to BV-2 
cells in presence of 0 or 50 ng/ml of LPS. After 24 h of treatment, the relative mRNA 
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expressions of M1 markers, IL6 (A) and iNOS (B) were analyzed via qRT-PCR. 
Experiments were performed in triplicates in three independent experiments. Relative 
transcripts levels of IL6 and iNOS in BV-2 cells treated with 0 ng/ml of LPS and 0 
ng/ml of HTRA1 served as control. Results were normalized to mouse ATPase 
transcript levels and calibrated with the control. The mean +/- SD for the three 
independent experiments are given.  
 
The addition of 50 ng/ml of LPS induced the M1 activation markers iNOS and IL6 in 
microglial cells. With the treatment of LPS, relative mRNA expressions of IL6 and 
iNOS show fold changes of 203.2 +/- 17.7 and 1088.5 +/- 65.3, respectively, 
compared to no LPS treatment. However, increasing concentrations of HTRA1 had 
no effect on the expression of these markers (Figure 23 A and B).  
   
4.7.2. Effect of HTRA1 on alternative activation of microglial (BV-2) cells 
via IL4 and TGF-β1 treatment 
IL4 is a well-described anti-inflammatory cytokine (Butovsky et al., 2005; Ledeboer et 
al., 2000; Park et al., 2005; Zhao et al., 2006), which induces alternative (M2) 
activation of microglia resulting in the expression of M2 markers Arginase 1 (Arg1) 
and Chitinase-3-Like-3 (Chi3l3 or Ym1) in microglial cells (Gordon, 2003; Ponomarev 
et al., 2007). TGF-β1 can enhance IL4-induced M2 activation of microglia by 
increasing the expression of Arg1 and Ym1 either by a direct effect on Ym1/Arg1 
promoter activity or indirectly by upregulating the IL4Rα, a receptor of IL4 (Zhou et 
al., 2012). 
Since HTRA1 plays a role in TGF-β signaling, role of HTRA1 in regulation of M2 
microglial activation was investigated. Alternative activation was achieved via IL4 and 
TGF-β1 treatment as described in Zhou et al. (2012). BV-2 cells, serum-starved for 
24 h, were treated separately or in combination with 1 ng/ml of TGF-β1 and 10 ng/ml 
of IL4 in presence of increasing Strep-tagged HTRA1 concentrations (30, 60, and 90 
ng/ml).  
 
Relative gene expression of both the M2 activation markers, Arg1 and Ym1 were 
analyzed via qRT-PCR. The results indicate that upon treatment of TGF-β1 alone 
there is no upregulation of the markers. In contrast, treatment of BV-2 cells with IL4 
alone upregulates the M2 markers. Furthermore, when treated with IL4 and TGF-β1, 
enhanced upregulation was observed in comparison to treatment with IL4 alone 
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(Figure 24A and B). These findings are in full agreement with the previous study by 
Zhou et al. (2012). 
 
Treatment of BV-2 cells with HTRA1 alone in increasing concentration shows no 
effect on gene expression of M2 markers. Increasing concentrations of HTRA1, in 
combination with TGF-β1, also does not show any effect on regulation of M2 
markers. However, HTRA1 shows an inhibition of M2 activation markers induced by 
IL4 alone and a combination of IL4 and TGF-β1 (Figure 24A and B). 
 
 
Figure 24: Effect of HTRA1 on relative mRNA expression of M2 markers of BV-2 
cells induced via IL4/ TGF-β1. Relative mRNA expressions of Arg1 (A) and Ym1 
(B) were analyzed by performing qRT-PCR of cDNA from serum-starved BV-2 cells, 
treated separately or in combination with 1 ng/ml of TGF-β1 and 10 ng/ml of IL4 in 
presence of increasing HTRA1 concentrations (30 ng/ml, 60 ng/ml, and 90 ng/ml). 
BV-2 cells, treated with increasing concentrations of HTRA1, in absence of IL4 and 
TGF-β1 were termed as “control”. Experiments were performed in triplicates in three 
independent experiments. Firstly, results were normalized to mouse ATPase 
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transcript levels. Results were then calibrated against transcript levels of the M2 
markers of BV-2 cells treated with 0 ng/ml of HTRA1, IL4 and TGF-β1 (A and B). 
Alternatively, results of each treatment (IL4 alone, TGF-β1 alone and IL4 along with 
TGF-β1) were separately calibrated with the respective transcript levels of the M2 
markers of BV-2 cells treated with 0 ng/ml of HTRA1 (C and D). Mean +/- SD for the 
three independent experiments are shown. Asterisks indicate significant (*P < 0.05) 
and highly significant (**P < 0.01) differences. 
 
More specifically, relative gene expression of Arg1 shows a downregulation by 79.0 
+/- 4.5%, 31.7 +/- 6.9% and 19.1 +/- 9.8% upon the treatment of BV-2 cells with IL4 in 
presence of 30, 60 and 90 ng/ml of HTRA1 compared to the treatment of BV-2 cells 
with IL4 in absence of HTRA1. (Figure 24 C). Similarly, relative gene expression of 
Ym1 gets reduced by 75.7+/- 13.7%, 41.7 +/- 11.8% and 18.8 +/- 8.4% upon 
treatment of BV-2 cells with IL4 in presence of 30, 60 and 90 ng/ml of HTRA1, 
compared to the treatment of BV-2 cells with IL4 in absence of HTRA1(Figure 24D). 
 
The relative gene expression of Arg1 shows a downregulation by 43 +/- 3.6%, 18.8 
+/- 5.4% and 4.47 +/- 1.2%, upon the treatment of BV-2 cells with IL4 and TGF-β1 in 
presence of 30, 60 and 90 ng/ml of HTRA1 compared to the treatment of BV-2 cells 
with IL4 in absence of HTRA1 (Figure 24C). Similarly, relative transcript levels of 
Ym1 show a downregulation by 24 +/- 2.5%, 7.8 +/-2.1% and 1.7 +/- 0.3%, upon the 
treatment of BV-2 cells with IL4 and TGF-β1 in presence of 30, 60 and 90 ng/ml of 
HTRA1 compared to the treatment of BV-2 cells with IL4 and TGF-β1 in absence of 
HTRA1 (Figure 24D). 
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5. DISCUSSION 
 
With around 14 million people affected worldwide, AMD is one of the most common 
causes of irreversible blindness (Resnikoff et al., 2004). AMD is a multifactorial 
disorder caused by both genetic and environmental influences. Polymorphisms in 
HTRA1 and ARMS2 on chromosome 10q26 are strongly associated with AMD. 
However, there are conflicting data regarding the involvement of these genes in the 
pathogenesis of AMD (Yang et al., 2006, Dewan et al., 2006, Kanda et al., 2007, 
Fritsche et al., 2008). In addition, there are speculations on an involvement of both 
genes in AMD development. (Yang et al., 2010).  
 
The involvement of HTRA1 in the development of AMD, through various signaling 
pathways, has been investigated in several studies. It was shown that overexpression 
of HTRA1 in a mouse model regulates angiogenesis through TGF-β signaling (Zhang 
et al., 2010). Another recent study also found an involvement of HTRA1 in IGF-1 
signaling. Two AMD-associated synonymous polymorphisms [(rs1049331 (c.102C>T) 
and rs2293870 (c.108G>T)] located in exon 1 of the HTRA1 gene were shown to 
directly influence the ability of HTRA1 to regulate insulin-like growth factor 1 (IGF1) 
signaling (Jacobo et al., 2013). A strong association of AMD pathology with these two 
variants located in exon 1 of the HTRA1 gene has been previously reported in 
several independent case-control association studies (Deangelis et al., 2008; Fritsche 
et al., 2008; Tam et al., 2008); however, the binding capacity of HTRA1 for IGF1 is 
contentious (Eigenbrot et al., 2012). 
 
5.1. Effect of synonymous polymorphisms within exon 1 of HTRA1 
on its structure and secretion 
In recent years, the influence of synonymous or silent mutations on protein folding 
and function has attracted increasing attention (Hunt et al., 2014). These alterations 
although not associated with changes in amino acid composition of the protein were 
reported to cause mRNA instability, exon skipping or alterations in co-translational 
protein folding (Duan and Antezana, 2003; Duan et al., 2003; Chamary and Hurst, 
2005; Chamary et al., 2006; Nackley et al., 2006; Kimchi-Sarfaty et al., 2007; 
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Chamary and Hurst, 2009; Zhang et al., 2010; Brest et al., 2011; Lampson et al., 
2013). As a consequence, synonymous alterations in protein-coding sequences may 
causally be involved in human pathologies. For example, synonymous changes in the 
multidrug resistance 1 (MDR1) gene were shown to cause an altered drug and 
inhibitor interaction leading to major changes in protein stability and transporter 
specificity (Kimchi-Sarfaty et al., 2007; Fung et al., 2014). A schizophrenia-associated 
synonymous SNP in the dopamine receptor D2 gene (DRD2) was also reported to 
alter the rate of translation (Duan et al., 2003).  
 
The first aim of the study was focused on the impact of three synonymous SNPs 
(rs1049331:C>T, rs2293870:G>T and rs2293870:G>C) on conformation of HTRA1. 
While rs1049331:C>T and rs2293870:G>T have been found to be associated with 
AMD, rs2293870:G>C despite being on the identical nucleotide position of 
rs2293870:G>T has not been found to be associated with the disease (Deangelis et 
al., 2008; Fritsche et al., 2008; Tam et al., 2008; Jacobo et al., 2013; Friedrich et al., 
2015). Hence, three expression constructs for HTRA1 were generated respectively 
including HTRA1 exon 1 variants rs1049331:C and rs2293870:G (referred to as 
HTRA1:CG), the AMD-associated variants rs1049331:T and rs2293870:T 
(HTRA1:TT), and the non-AMD-associated variants rs1049331:C and rs2293870:C 
(HTRA1:CC). Thermophoretic movement of the three different isoforms was analyzed 
by MST. This technique is based on thermophoresis, the directed motion of 
molecules in temperature gradients. Thermophoresis is highly sensitive to all types of 
binding-induced changes of molecular properties, be it in size, charge, hydration shell 
or conformation (Seidel et al., 2013). It has recently been demonstrated that MST is 
well-suited to follow protein unfolding and to detect unfolding intermediates, and that 
it rivals more traditional approaches such as circular dichroism or tryptophan 
fluorescence measurements in this capacity due to its speed and low sample 
consumption (Alexander et al., 2013). Because of its high sensitivity to 
conformational change, MST qualifies as a good technique to study the 
conformational change caused by synonymous polymorphisms. In the present study, 
thermophoretic movement of HTRA1 were significantly altered for the protein isoform 
HTRA:TT, but not for the two other isoforms, HTRA1:CG or HTRA1:CC. MST results 
were confirmed by performing limited proteolysis assay, which is an established 
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technique for protein conformation studies (Varne et al., 2002; Huang, 2003; Fontana 
et al., 2004). These assays documented an altered accessability of HTRA1:TT 
isoform compared to HTRA1:CG isoform, clearly indicating structural differences of 
both isoforms. This is in full agreement with findings first reported by Jacobo et al. 
(Jacobo et al., 2013). In their work, the authors observed a decreased translation rate 
of the isoform HTRA1:TT, which they ascribed to differential codon usage (Jacobo et 
al., 2013). Synonymous codons are distinguished by the abundance of their 
corresponding tRNA, which is lower for rare codons than for the frequent codons 
(Cannarozzi et al., 2010; Tuller et al., 2010). Folding of nascent polypeptides occurs 
cotranslationally (Frydman et al., 1994; Makeyev et al., 1996) and is influenced by the 
rate of ribosome transit through the mRNA template. Therefore, codon frequency can 
influence the rate of translation. The hypothesis that the attainment of a 
conformationally immature protein with functional deficits is caused by the decreased 
protein translation owing to common-to-rare codon conversion is consistent with 
several publications (Zhang et al., 1998; Komar et al., 1999; Kimchi-Sarfaty et al., 
2007; Bartoszewski et al., 2010). 
 
Secreted proteins undergo stringent ER quality control (Ruggiano et al., 2014). 
Synonymous SNPs in Cystic Fibrosis Transmembrane Region (CFTR) causes local 
misfolding of the protein and retention of the protein in ER for a prolonged time 
(Zhang et al., 1998; Bartoszewski et al., 2010). That’s why time-dependent secretion 
was monitored to compare the secretory property of the two conformationally different 
HTRA1 isoforms. The results indicated that HTRA1:TT had a decreased secretion as 
well as intracellular aggregation when compared to HTRA1:CG. Whether delayed 
secretion or intracellular aggregation of HTRA1 or both could affect the progression 
of AMD is yet to be clarified. 
 
5.2. Effect of synonymous polymorphisms within exon 1 of HTRA1 
on its substrate specificity 
As a conformational change in the AMD risk-associated isoform was suggested, the 
impact of the changes on substrate specificity of HTRA1 was the next the thing to be 
investigated in our study. HTRA1 is a serine protease having an array of substrates. 
HTRA1 digests major components of cartilage, such as aggrecan, decorin, 
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fibromodulin and soluble type II collagen (Tsuchiya et al., 2005). Various other 
substrates of HTRA1 that are associated with the complement system (clusterin, 
vitronectin and fibromodulin) were found in supernatants of primary RPE cells (An et 
al., 2010). An et al. (2010) additionally confirmed the proteolytic breakdown of 
clusterin by recombinant HTRA1 via in vitro digestion. The pro form of complement 
factor D (CFD) is cleaved by HTRA1 to activate CFD (Stanton et al., 2011). In 
addition to these complement proteins, An et al.(2010) also demonstrated proteins 
involved in the amyloid deposition (clusterin, alpha-2 macroglobulin and ADAM9) as 
interaction partners of HTRA1. Amyloid is a component of drusen and it could be 
shown that HTRA1 co-localized with so-called amyloid plaques in the brain of 
Alzheimer's disease patients (Grau et al., 2005; Cameron et al., 2007). Grau et al. 
(2005) identified the amyloid precursor protein C99 as substrate of HTRA1 by 
showing its cleavage by recombinant HTRA1 in vitro. Many ECM-associated 
substrates that are cleaved by HTRA1 such aggrecan, biglycan, decorin, 
fibromodulin, fibronectin, soluble type II collagen and elastin were identified (Tsuchiya 
et al., 2005; Chamberland et al., 2009; Jones et al., 2011). The study by Vierkotten et 
al. (2011) was able to demonstrate that fibronectin, fibulin 5 and nidogen 1 are 
digested in vitro by recombinant HTRA1, whereas, laminin and collagen type IV were 
not digested by recombinant HTRA1 in vitro (Vierkotten et al., 2011). Jacobo et al. 
(2013) also reported differential affinities of AMD-associated HTRA1 (HTRA1:TT) 
variant towards IGF-1 interaction. However, the interaction between HTRA1 and IGF-
1 is challenged by findings from Eigenbrot et al. (2012) who failed to obtain any 
evidence for binding of IGF-I or IGF-II, or insulin-binding activity by the N-domain of 
HTRA1. This is further supported by a biosensor binding study which found no 
appreciable Mac-25 interaction of HTRA1 with IGF-I or IGF-II (Vorwerk et al., 2002).  
 
Among all the substrates of HTRA1, interaction with family of TGF-β proteins is the 
most widely studied (Oka et al., 2004; Launay et al., 2008; Shiga et al., 2011; Zhang 
et al., 2012; Graham et al., 2013; Karring et al., 2013). In several studies, HTRA1 has 
been shown to inhibit TGF-β signaling but the exact mechanism of the inhibition 
remains controversial. Shiga et al. (2011) describes that HTRA1 binds to pro-TGF-β 
and cleaves it intracellularly, more precisely in the endoplasmic reticulum (ER). The 
cleavage thereby inhibits TGF-β signaling. Oka and colleagues (2004), however, 
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showed an extracellular digestion of the secreted active TGF-β by HTRA1. In another 
independent study, in vitro digestion of TGF-β by HTRA1 was confirmed (Launay et 
al., 2008). In an HTRA1-deficient mouse model, increased mRNA expression of 
GDF6, a TGF-β family member, was observed. This mouse model showed increased 
TGF-β signaling and increased vascularization of the retina (Zhang et al., 2012). It 
has recently been reported that overexpression of HTRA1 causes reduced levels of 
TGF-β receptors type II and III: HTRA1 was found to digest the TGF-β receptors type 
II and III in vitro, but not the receptor type I or TGF-β (ligand) (Graham et al., 2013). 
All these contradictory studies show that it is still under discussion, how HTRA1 
inhibits TGF-β signaling (Oka et al., 2004; Shiga et al., 2011; Graham et al., 2013). 
Since the TGF-β signaling is also closely linked to the VEGF-A signaling (Clifford et 
al., 2008), regulation of TGF-β by HTRA1 could possibly also affect angiogenesis in 
the eye influencing the progress of CNV. 
 
In this work, an interaction between HTRA1 and TGF-β1 was investigated using MST 
and in vitro proteolysis assay. MST has been successfully applied to study the 
protein-protein interaction in a variety of studies (Arbel et al., 2012; Lin et al., 2012; 
Wilson et al., 2012; Keren-Kaplan et al., 2013; Xiong et al., 2013; Zillner et al., 2013). 
While a typical sigmoidal binding curve was observed in MST analyses of direct 
interaction between HTRA1:CG and TGF-β1, no stable interaction between 
HTRA1:TT and TGF-β1 was observed. In addition, evidence for a direct proteolytic 
activity of isoform HTRA1:CG towards mature TGF-β1 was obtained via in vitro 
digestion assay. In contrast, the in vitro digestion assay suggested a strongly 
decreased turnover rate of TGF-β1 by HTRA1:TT compared with HTRA1:CG. The 
apparent discrepancy raises the question why there is still an interaction of TGF-β1 
and HTRA1 in the proteolysis assay, whereas at the same time, no interaction of the 
two proteins is apparent in the MST assay. It is hypothesized that a stable interaction 
between HTRA1 and TGF-β1 is measured by MST, resulting in a binding constant 
whereas the proteolytic assay measures enzyme kinetics over a longer period of 
time. A stable interaction between protease and substrate is not indispensible for 
proteolytic cleavage, as described, for example, in rhomboid proteases (Dickey et al., 
2013). Although no physiological affinity of these proteases for their substrates were 
displayed, an approximate 10,000-fold difference in proteolytic efficiency with 
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substrate mutants and diverse rhomboid proteases were reflected in kcat values 
alone. 
  
5.3. Effect of HTRA1 variants on TGF-β signaling 
As the AMD-associated HTRA1 isoform exhibited decreased affinity for TGF-β1, the 
next step was to investigate whether this also affects TGF-β-mediated signaling 
pathways. Reporter assay using MLEC-PAI/Luc is a widely used bio-assay for 
quantification of TGF-β signaling (Abe et al., 1994; Shibuya et al., 2006; Zhou et al., 
2012). It was observed that the differential effect of HTRA1 isoforms on proteolysis of 
TGF-β1 subsequently affected its regulation of TGF-β signaling, adressed in reporter 
assays assessing the PAI-1 promoter, a prominent target of the TGF-β cascade. 
Hara et al. (2009) reported similar consequences due to CARASIL-associated 
HTRA1 variants. Specifically, two nonsense and one missense mutation in HTRA1 
resulted in protein products that failed to repress signaling by the TGF-β family (Hara 
et al., 2009). As increased TGF-β levels were observed in cerebral arteries of 
CARASIL patients, the authors concluded that HTRA1 contributes to the pathogenic 
processes of CARASIL via its control of TGF-β signaling. In this context, it is 
interesting to note that increased TGF-β levels are also observed in AMD patients 
(Guymer et al., 2011; Bai et al., 2014) and aberrant TGF-β signaling was connected 
to AMD-related phenotypes in mice (Lyzogubov et al., 2011; Promsote et al., 2014) 
and RPE cells (Yu et al., 2009a; Yu et al., 2009b; Vidro-Kotchan et al., 2011; 
Promsote et al., 2014). This and our findings could imply a role for HTRA1 in AMD 
pathogenesis via its regulation of the TGF-β pathway.  
 
Our results also demonstrated control of HTRA1 over TGF-β regulation in cultured 
microglial cells. Microglia are the major resident inflammatory cells of the central 
nervous system and obtain key functions of immune surveillance and tissue repair 
(Kreutzberg, 1996; Tambuyzer et al., 2009; Hughes, 2012). Thus, this cell type is 
deeply involved in the pathogenic processes of various neurodegenerative diseases 
like Parkinson’s disease (Schapansky et al., 2015), Alzheimer’s disease (Bamberger 
and Landreth, 2002; D'Andrea et al., 2004; Streit et al., 2008; Latta et al., 2015; Lue 
et al., 2015), Amyotrophic lateral sclerosis (ALS) (Boillee et al., 2006; Henkel et al., 
2009; Brites and Vaz, 2014), inherited retinopathies (Langmann, 2007; Karlstetter et 
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al., 2010) or AMD (Ma et al., 2009; Damani et al., 2011; Ma et al., 2013; Wong, 2013; 
Karlstetter and Langmann, 2014). 
 
Aging is associated with increased numbers of retinal microglia in mice, and along 
with tissue stress or injury, aging causes retinal microglia to undergo phenotypical 
changes whereby they become larger and less dendritic, which are typical 
morphological signs of activation (Xu et al., 2009). While microglia are generally 
believed to return to their ramified phenotype and leave the subretinal space once the 
injury has subsided, the response of aging microglia to injury is slower and less 
reversible (Langmann, 2007). Moreover, during an insult or injury, microglia migrate 
from the inner retina to the subretinal space, which is normally devoid of microglia. 
The importance of subretinal accumulation of activated microglia in AMD is not clear, 
but could be both a symptom of inflammatory damage and a beneficial response to 
injury, since infiltration of microglia/macrophages to sites of retinal injury may 
promote neovascularization, while impairment of this accumulation in the subretinal 
space exacerbates retinal degeneration (Sakurai et al., 2003; Ma et al., 2009; Ambati 
et al., 2013). Another study reported the role of microglia in the local control of 
complement activation in the retina and presented the age-related accumulation of 
ocular lipofuscin in subretinal microglia as a cellular mechanism capable of driving 
outer retinal immune dysregulation in AMD pathogenesis (Ma et al., 2013). Microglial 
cells express VEGF receptors and eyes treated with anti-VEGF showed a 
significantly decreased number of activated microglia in the retina and the choroid. 
This suggests that the beneficial effects of anti-VEGF therapy in wet AMD may 
exceed its vascular effects (Couturier et al., 2014). 
 
Activation and differentiation of microglia is strongly regulated by TGF-β signaling 
(Rozovsky et al., 1998; Huang et al., 2010; Cekanaviciute et al., 2014; Norden et al., 
2014). TGF-β is a pleiotropic cytokine that has inflammatory and anti-inflammatory 
activities depending on the cellular environment of the innate immune cells [reviewed 
in (Letterio and Roberts, 1998; Wan and Flavell, 2007)]. The maintenance of the 
normal retinal immune regulation seems to actively involve TGF-β from the RPE. 
TGF-β contributes to the immune privilege by predisposing microglia to the 
preferential production of IL10, which in turn downregulates antigen-presenting 
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molecules including MHC-II, CD80 and CD86 (D'Orazio and Niederkorn, 1998). TGF-
β also directs TNF/IFN-γ-stimulated microglia cells to an anti-inflammatory phenotype 
by broadly blocking inflammatory gene expression (Paglinawan et al., 2003). 
Therefore, our next aim was to compare the effect of HTRA1 variants on regulation of 
TGF-β signaling in BV-2 microglial cells. The results showed that phosphorylation of 
SMAD2 and Pai-1 expression, both markers for activated TGF-β signaling (Cao et al., 
1995; Kutz et al., 2001; Dong et al., 2002; Javelaud and Mauviel, 2004a, b, 2005), 
were significantly lower in microglial (BV-2) cells treated with HTRA1. Thus, our data 
further provide evidence for a role of HTRA1 in the differentiation and activation of 
microglia, and therefore likely in the pathogenesis of neurodegenerative diseases. 
Notably, the inhibitory effect of HTRA1:TT on microglial TGF-β signaling was weaker 
compared to the reference HTRA1 isoform, HTRA1:CG. In a mouse model of another 
adult-onset neurodegenerative disease, ALS, TGF-β1 was found to inhibit the 
neuroprotective response by microglia and T cells. A TGF-β signaling inhibitor slowed 
the disease progression and extended survival of the mice (Endo et al., 2015). In a 
mouse model of Alzheimer’s disease, blockade of TGF-β–SMAD2/3 signaling in 
innate immune cells is shown to reduce senile plaque formation in the brain 
parenchyma (Town et al., 2008). So, it can be speculated that the altered regulation 
of TGF-β signaling in AMD might enhance the pathogenesis of AMD. 
 
5.4. Effect of HTRA1 on classical and alternative microglial 
activation  
To give first insights into a possible involvement of HTRA1 in microglial activation, the 
effect of HTRA1 on classical (M1) and alternative (M2) activation of microglial cells 
was included in this study. Microglia can be activated by the cytokines interferon-γ 
(IFN-γ), interleukin-17 (IL17) or LPS into a proinflammatory phenotype (M1), whereas 
IL4 or IL13 induce a state of anti-inflammatory phenotype (M2), which is associated 
with neuroprotective functions that promote repair (Butovsky et al., 2006b; 
Ponomarev et al., 2007; Kawanokuchi et al., 2008). IL4 and IL13 suppress the 
production of pro-inflammatory cytokines such as IL8, IL6 and tumor necrosis factor-α 
(TNF-α), and reduce nitrite release, which collectively protect against LPS/IFN-γ-
induced M1 microglial activation in vitro and in vivo (Ledeboer et al., 2000; Butovsky 
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et al., 2005; Park et al., 2005; Zhao et al., 2006). Counteracting pro-inflammatory 
cytokines is accompanied by the induction of typical M2 markers, such as Arginase 1 
(Arg1), Chitinase-3-Like-3 (Chi3l3 or Ym1), Mannose receptor (CD206) and Found in 
inflammatory zone 1 (FIZZ1) (Gordon, 2003; Ponomarev et al., 2007). Anti-
inflammatory factors are also released by M2 microglia when apoptotic cells or myelin 
debris are removed (Liu et al., 2006). Neurotrophic factors, such as insulin-like 
growth factor 1 (IGF-I) are also released by M2 microglia to assist inflammation 
resolution and promote neuron survival (Suh et al., 2013). It is postulated by many 
studies that acquired deactivation by anti-inflammatory cytokines such as IL10 and 
TGF-β is another state of M2 activation to alleviate acute inflammation and is induced 
primarily by uptake of apoptotic cells or exposure to insult or injury (Qin et al., 2006; 
Colton, 2009; Colton and Wilcock, 2010). Notably, the neuroprotective signals of 
alternative activation and acquired deactivation orchestrate each other in a 
coordinated way against the proinflammation responses. For example, TGF-β can 
enhance IL4-induced M2 microglia by increasing the expression of Arg1 and Ym1. 
Exogenous TGF-β1 enhances IL4-induced Ym1 and Arg1 expression either by a 
direct effect on Ym1/Arg1 promoter activity or indirectly by upregulating the IL4Rα, 
receptor of IL4, through activation of the MAP kinase pathway. Furthermore, 
treatment with IL4 shows increase in the expression and secretion of endogenous 
TGF-β2. Autocrine TGF-β2 in turn might be able to enhance IL4-induced Arg1 
expression similar to exogenous TGF-β1 (Zhou et al., 2012). 
 
No effect of HTRA1 on 50 ng/ml LPS-induced M1 microglial cells was detected in our 
study. However, the possibility of any effect of HTRA1 on M1 activation cannot be 
ruled out. 50 ng/ml LPS is a very high stimulus for classical activation, giving almost 
maximal activation. Weak effects by HTRA1 could simply be superimposed by the 
strong stimulus. Therefore, it is needed to be confirmed whether HTRA1 has an effect 
on M1 markers induced by a lower dose of LPS. Furthermore, it has been proposed 
that LPS interferes with key components in the TGF-β1 signaling pathway in primary 
microglia. The study showed that the ability of TGF-β1 to exert anti-inflammatory 
effects is significantly reduced by LPS leading to prolonged survival of M1 microglia, 
although the exact mechanism remains to be clarified (Mitchell et al., 2014). As 
HTRA1 has been shown to have an interaction with TGF-β1 and plays a role in TGF-
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β1 signaling, to investigate an effect of HTRA1 in regulation of TGF-β1 signaling in 
LPS-stimulated microglia would be interesting. 
 
Next, the effect of HTRA1 on M2 microglial activation was investigated. HTRA1 has 
been shown to downregulate induced alternative activation (M2) markers of BV-2 
cells, Arg1 and Ym1 induced by IL4 alone and IL4 in combination with TGF-β1. The 
downregulation of M2 microglial activation induced by a combination of IL4 and TGF-
β1 can be explained by the capacity of HTRA1 to cleave TGF-β1 (as shown earlier). 
Interestingly, HTRA1 also downregulates expression of Arg1 and Ym1 induced by IL4 
alone. As mentioned before Zhou et al. (2012) demonstrated that IL4-induced Arg1 is 
also dependent on autocrine TGF-β2 signaling. Our results could therefore be 
explained by HTRA1 cleaving the endogenously produced and secreted TGF-β or 
TGF-β receptors type II and III, as suggested by Graham et al. (2013).  
 
Even though this study is a preliminary study, it is first of its kind to show a novel role 
of HTRA1 in regulation of M2 microglial activation. Nevertheless, further read-outs 
like Arginase assay or studies on microglial morphology are needed to confirm these 
first results. It also requires more precise understanding of the exact mechanism of 
action of HTRA1 in downregulating IL4-induced alternative activation. It is to be noted 
that here only non-AMD-associated HTRA1 (HTRA1:CG) isoform was used for 
treating the BV-2 microglial cells. To connect this study with reference to AMD 
pathogenesis, the foremost requirement would be to include AMD-associated HTRA1 
isoform (HTRA1:TT) to compare the effects of both HTRA1 isoforms on the activation 
markers. Till date, two independently studied HTRA1 transgenic mice models showed 
AMD-like phenotypes (Jones et al., 2011; Vierkotten et al., 2011). More detailed 
studies of the microglia of the HTRA1 transgenic mice may unravel a novel role of 
HTRA1 in AMD pathogenesis from an immunological point of view.
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6. CONCLUSION 
 
Taken together, our data show that HTRA1 is an important regulator of TGF-β 
signaling by direct interaction and cleavage of TGF-β. AMD-associated 
polymorphisms in HTRA1 [rs1049331 (c.102C>T) and rs2293870 (c.108G>T)] result 
in delayed protein secretion, reduced TGF-β1 affinity, and decreased capacity to 
control TGF-β signaling and autocrine TGF-β regulation in microglia. One might be 
tempted to speculate a functional contribution of AMD-associated polymorphisms in 
HTRA1 to AMD pathogenesis, via their effect on the affinity of HTRA1 for TGF-β. 
Nevertheless, other so-far-unknown sites of interaction at which HTRA1 antagonizes 
the TGF-β pathway (or might influence cellular processes involved in AMD 
pathogenesis) cannot be excluded. Moreover, it has also been shown that gene 
expression of HTRA1 is highly heterogeneous among different individuals, 
independent of their HTRA1 genotype (Friedrich et al., 2011), with expression levels 
of HTRA1 varying up to 20-fold. In principle, this questions an involvement of reduced 
HTRA1 activity on AMD development. In addition, due to high LD within the 
chromosomal HTRA1 gene locus, a number of additional polymorphisms reveal an 
equally strong association with AMD extending to and encompassing variants at the 
neighboring ARMS2 gene. The final decision about which gene, HTRA1 or ARMS2, 
is causally involved in AMD pathogenesis requires further scrutiny and specifically 
needs the understanding of functional aspects of the as-of-yet unknown ARMS2 
protein. 
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AMD Age-related Macular Degeneration 
Ampr Ampicillin resistant 
APS Ammonium Per Sulphate 
ATP Adenosine Triphosphate 
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